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1. Introduction  
 
“The diagnosis of breast cancer is one of the cruelest as bizarre at the same time thing 
that can happen in a woman’s life: you are fine, nothing bothers you, and suddenly, 
taking a shower you realize, or your doctor visiting you realizes that un-aching lymph 
threatens your life. The contrast between the perceptible reality- feeling apparently fine, 
living a normal life- and the one hidden- the disease, the view of the end of the road- is a 
shocking experience, a drama that an increasing number of women experience.” 
1
 
I wanted to start my work with the words of one person, Prof.Dott Umberto Veronesi, 
who dedicated his work to this cause and who maybe was the first to see the aggressivety 
of the disease and of its own treatment as a debilitating fact in a woman’s life for many 
reasons.  
The aim of my thesis is creating a quality diagnostic breast center format based on 
European guidelines and international models. The necessity of having such a format 
derives from the study of the breast disease and from the difficulty of dealing with this 
kind of patients. The breast cancer is a disease that time and experience has shown to be 
multidisciplinary concern pathology. A single physician cannot take proper care of a 
woman affected but such a disease. The difficulty is not only in diagnosing, treatment and 
prevention but also dealing with the patient’s emotional and psychological sphere 
derived from the physical change. Even though the pathology is the same worldwide the 
                                                           
1
 Umberto Veronesi “le donne devono sapere” 
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difference and difficulty consist in the information of women, their emancipation in 
society and their religious belief. A very important aspect is also the geography, not only 
because it influences the lifestyle, diet epidemiologic factors etc but also because in some 
countries in the world being a woman means also being neglected from the entire society 
and this brings to fear of explaining pain and changes in a part of the body related just to 
the sexuality of a woman( that is traduced in shame in a lot of cultures), geography does 
not affect our topic only in this aspect but also in managing of the diagnosing- treatment 
process. Living in rural places that have hospitals not provided with the necessary 
equipment and lack of specialized physicians effects negatively the prognosis and the 
early diagnosis of the breast cancer. 
The decision to treat this topic came out from the differences detected in different 
countries and cultures (Albania, Turkey, and Italy) that are different politically talking and 
socially talking, this brings in formation of totally different models of approach to the 
disease and different outcomes. 
The variables that bring these differences are the development (the most important), the 
religion, the prevention campaign and information, formation of specialized and 
experienced doctors.  
In the later chapters I will talk about each of the models and their outcome, but first I 
want to talk about the creation of the breast center, a multidisciplinary center 
coordinated to provide the best treatment to every single patient. 
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2. Definition of breast center 
There have been several meetings and conferences in order to work out guidelines to 
offer a quality treatment to breast cancer affected patients. There have been several 
statements over the years (Florence Statement, Brussels Statement, Barcelona 
Statement, Hamburg Statement, Nice Manifesto etc), their aim is to: 
• co-ordinate breast cancer research 
• educate primary care providers in breast center issues 
• sensitize politicians and women to the problems surrounding the disease 
In 2000 EUSOMA, the European Society of Breast Cancer Specialists published a position 
paper ‘The Requirements of a Specialist Breast Unit’
2
. This document represented the 
starting point towards accomplishing of what was demanded by the consensus statement 
3
of the first European Breast Cancer Conference (EBCC1) that all women have access to 
fully equipped multidisciplinary and multi professional breast clinics based on populations 
of around 250,000 and that quality assurance program for breast services should become 
mandatory. This paper has now been widely accepted and recognized as a benchmark for 
the set-up of a Breast Centre.  
                                                           
2
 Blamey RW, Cataliotti L, et al. The requirements of a specialist breast unit. Eur J Cancer 2000;36:2288–93. 
3
 Cataliotti L, Costa A, Daly PA, et al. Florence statement on breast cancer, 1998: forging the way ahead for 
more research on and better care in breast cancer. Eur J Cancer 1999; 35(1):14–5. 
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 Breast Centre is the place where breast cancer is diagnosed and treated. It has to provide 
all the services necessary, from genetics and prevention, through the treatment of the 
primary tumor, to care of advanced disease, palliation and survivorship. 
The Breast Centre is made up by a cohesive group of dedicated breast cancer specialists 
working together as a multidisciplinary team with access to all the facilities required to 
deliver high quality care throughout the breast cancer pathway. This group does not 
necessarily have to be a geographically single entity, as the Breast Centre can be made up 
by services and specialists from more than one hospital, within the same geographical 
area, allowing for close multidisciplinary working and guarantee easy access to all the 
necessary services. 
 
There must be an official formal document (that complies with any national regulations) 
that demonstrates the set-up of the Breast Centre. The Breast Centre is encouraged to 
make a cost evaluation of its activity on a yearly basis. 
A Breast Centre must be of sufficient size to have at least 150  newly diagnosed cases of 
primary breast cancer (at all ages and stages together) coming under its care each year, 
on a population base of about 250.000 
4
 
5
. The reason for recommending a minimum 
number is to ensure a caseload sufficient to maintain expertise for each team member 
and to ensure cost-effective working of the Breast Center
6
. There is now also good data 
that shows that breast cancer survival is related to the number of cases treated per 
                                                           
4
 Rainsbury D,Willett A, on behalf of BAPRAS. British Association of Plastic Reconstructive and Aesthetic 
Surgeons. Oncoplastic breast reconstruction guidelines for best practice. Association of Breast Surgery; 
2012, 1–64. www.associationofbreastsurgery.org.uk 
5
 Hoffmann J. Analysis of surgical and diagnostic quality at a specialist breast unit. Breast 2006; 15: 490–7. 
6
 Vrijens F, Stordeur S, Beirens K, Devriese S, Van Eycken E, Vlayen J. Effect of hospital volume on processes 
of care and 5-year survival after breast cancer: a population-based study on 25000 women. Breast 2012; 
21(3):261–6. 
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annum
7
. Cases to be counted may have been diagnosed elsewhere, but without receiving 
any breast cancer treatment elsewhere. All primary treatments must be carried out under 
the direction of the Breast Centre (surgery must be carried out in the Breast Centre, 
adjuvant therapies must be agreed at the MDM by the Breast Centre team but may be 
given in another site e.g. radiation oncology and chemotherapy). 
A breast center, as I am trying to explain through the guidelines and the directions made 
out in different congresses, meetings, publications and EUSOMA, is a centre not only 
physically talking but it is a grouping of specialized doctors, nurses and co-workers. I will 
talk later explaining by definition and also role and models about every component of a 
breast centre. The members that compose a breast center are several:   
Breast specialist: A person certified in her/his own discipline and fully trained in breast 
disease. 
Breast core team member: Radiologist, radiographer, surgeon, reconstructive surgeon, 
pathologist, medical oncologist, radiation oncologist, breast care nurse, and data 
manager consistently spending at least part of their working time in breast cancer (see 
sections on the different specialties for the expected working time recommendations). 
Breast radiologist: A specialist in the imaging for diagnosis (including interventional 
procedures), further assessment and follow up of breast cancer patients. 
Breast radiographer: A technician that is specialist in performing mammography and 
committed to achieving mammographic quality. 
Breast surgeon and reconstructive surgeon: A specialist in general surgery, reconstructive 
surgery or gynecology with a special interest in breast disease. 
                                                           
7
 Kwaliteitsindicatoren in oncologie: borstkanker KCE reports 150A; Federaal Kenniscentrum voor de 
Gezondheidszorg, Centre fe´de´ral d’expertise des soins de sante´; 2010. 
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Breast pathologist: A board certified specialist in pathology with a special interest to 
breast disease. 
Breast medical oncologist: A specialist in medical oncology with a special interest in 
breast disease. 
Breast radiation oncologist: A specialist in radiation oncology with a special interest in 
breast disease. 
Breast clinical oncologist: In some countries clinical oncologists carry out both radiation 
therapy and medical treatment. In the remaining of this paper, clinical oncology can be 
read wherever medical or radiation oncologist is written. 
Breast care nurse: A nurse with specialist training in breast care nursing. 
Breast data manager: A trained and dedicated person responsible for breast data 
management. 
Non-core team members: Specialists who are consulted during the breast cancer patient 
management, who are not routinely involved in breast cancer care of each patient. 
Clinical geneticist: A medical specialist concerned with the assessment of genetic risk and 
counseling for individuals or families with increased risk of breast cancer. 
Psychologist: Dedicated to the psychological support to breast patients. Not usually 
medically qualified and therefore not authorized to prescribe pharmacological therapies. 
Psychiatrist: Medically qualified specialist in psychological and pharmacological treatment 
of patients with psychiatric and psychological problems. 
Physiotherapist: Dedicated to the physical support of patients after breast surgery. 
Lymphatic drainage specialist: Dedicated to treat specifically problems related to 
disturbed lymphatic drainage after treatment in breast cancer patients. 
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Breast care worker: Qualified care provider (other than nurse; e.g. radiation therapy 
technologist), trained to give psychological support to breast cancer patients and to act 
during treatment (e.g. radiation therapy) and follow up as link between patients and the 
breast team. 
Obviously this is a large staff that requires a clinical lead and protocols to make the 
mechanism work properly and have good results talking about quality in diagnosis and 
prevention of breast cancer. 
This is a panoramic description of a Breast Center, I am going to discuss every component 
in details to give a better idea of what all these protocols are about but first I want to talk 
about the breast and its diseases so that diagnosis will be easier to understand. 
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3. Anatomy Callings 
 
The breast lies between the subdermal layer of adipose tissue and the superficial pectoral 
fascia. The breast parenchyma is composed of lobes that in turn are comprised of 
multiple lobules. There are fibrous bands that provide structural support and insert 
perpendiculary into the dermis, termed the suspensory ligaments of Cooper. Between the 
breast and the pectoralis major muscle lies the retromammary space,a thin layer of loose 
aereolar tissue that contains lymphatic and small vessels. 
Located deep to the pectoralis major muscle, the pectoralis minor muscle is enclosed in 
the clavipectoral fascia, which extends laterally to fuse with the axillary fascia. The axillary 
nodes are found within the loose aereolar fat of the axilla; the number of the lymph 
nodes is variable, depending on the size of the patient. The number of lymph nodes 
recovered from pathologic examination of Halsted –type
8
 mastectomy speciments is 
approximately 50 nodes. 
The axillary nodes are typically described as three anatomic levels defind by their 
relationship to the pectoralis minor muscle. Level 1 nodes are located lateral to the lateral 
border of the pectoralis minor muscle. Level 2 nodes are located posterior to the 
pectoralis minor muscle. Level 3 nodes include the subclavicolar nodes medial to the 
pectoralis minor muscle. The level 3 nodes are easier to visualize and remove when the 
pectoralis muscle is divided. The apex of the axilla is defined by the costoclavicular 
                                                           
8
  Halsted performed the first radical mastectomy for breast cancer in the US; an operation first performed 
in France a century earlier by Bernard Peyrilhe (1735-1804) 
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ligament (Halsted s ligament), at which point the axillary vein passes into the thorax and 
becomes the subclavian vein. Lymph nodes in the space between pectoralis minor and 
major muscles are termed the interpectoral group, or Rotter s nodes, as described by 
Grossman and Rotter. 
Lymphatic channels are abundant in the breast parenchyma and dermis. Specialized 
lymphatic channels collect under the nipple and areola and from Sappey s plexus, named 
for the anatomist who described them in 1885. Lymph flows from the skin to the 
subareolar plexus and then into interlobular lymphatics of the breast parenchyma. 
Appreciation of lymphatic flow is important for performing sentinel lymph node surgery. 
Of lymphatic flow from the breast, 75% is directed into the axillary lymph nodes. A minor 
amount goes through the pectoralis muscle and into more medial lymph node groups. 
Lymphatic drainage also occurs through the internal mammary lymph nodes as the 
predominant drainage in up to 5% of patients and as a secondary route in combination 
with axillary drainage in approximately 20%. A major route of breast cancer metastasis is 
through lymphatic channels; the regional spread of cancer is important to understand to 
provide optimal locoregional control of disease. 
Coursing close to the chest wall on the medial side of the axilla is the long thoracic nerve, 
or the external respiratory nerve of Bell, which innervates the serratus anterior muscle. 
This muscle is important for fixing the scapula to the chest wall during adduction of the 
shoulder and extension of the arm, and division of the nerve may result in the winged 
scapula deformity. For this reason, the long thoracic nerve is preserved during axillary 
surgery. The second major nerve encountered during axillary dissection is the 
thoracodorsal nerve, which innervates the latissimus dorsi muscle. This nerve arises from 
the posterior cord of the brachial plexus and enters the axillary space under the axillary 
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vein, close to the entrance of the long thoracic nerve. It then crosses the axilla to the 
medial surface of the latissimus dorsi muscle. The thoracodorsal nerve and vessels are 
preserved during dissection of the axillary lymph nodes. The medial pectoral nerve 
innervates the pectoralis major muscle and lies within a neurovascular bundle that wraps 
around the latelar border of the pectoralis minor muscle. The pectoral neurovascular 
bundle is a good landmark in that indicates the position of the axillary vein, which is just 
cephalad and deep (superior and posterior) to the bundle. This neurovascular bundle 
should be preserved during standard axillary dissection. 
The large sensory intercostal brachial or brachial cutaneous nerves span the axillary space 
and supply sensation to the undersurface of the upper part of the arm and skin of the 
chest wall along the posterior margin of the axilla. Dividing these nerves results in 
cutaneus anesthesia in these aereas and should be explained to patients before axillary 
dissection. Denervation of the areas supplied by these sensory nerves can cause chronic 
and uncomfortable pain syndromes in a small percentage of patients. Preservation of the 
superiormost nerve maintains sensation to the posterior aspect of the upper part of the 
arm intact without compromising the axillary dissection in most patients. 
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Microscopic anatomy 
 
The mature breast is composed of three principal tissue types: (1) glandular epithelium; 
(2) fibrous stroma and supporting structures; and (3) adipose tissue. Lymphocites and 
macrophages are also found within the breast. In adolescents, the predominant tissues 
are epithelium and stroma. In postmenopausal women, the glandular structures involute 
and are largely replaced by adipose tissue. Coopers ligaments provide shape and 
structure to the breast as they course from the overlying skin to the underlying deep 
fascia. Because they are anchored into the skin, infiltration of these ligaments by 
carcinoma commonly produces tethering which can cause dimpling or subtle deformities 
on the otherwise smooth surface of the breast. 
The glandular apparatus of the breast is composed of a branching system of ducts, 
roughly organized in a radial pattern spreading outward and downward from the nipple-
areolar complex. It is possible to cannulate individual ducts and visualize the lactiferous 
ducts with contrast agents. Each major duct has a dilated portion (lactiferous sinus) below 
the nipple-areolar complex. These ducts converge through a constricted orifice into the 
ampulla of the nipple. 
Each of the major ducts has progressive generations of branching and ultimately ends in 
the terminal ductules or acini. These acini are the milk-forming glands of the lactating 
breast and, together with their small efferent ducts or ductules, are known as lobular 
units or lobules. The terminal ductules are invested in a specialized loose connective 
tissue that contains capillaries, lymphocites, and other migratory mononuclear cells. This 
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intralobular stroma is clearly distinguished from the denser and less cellular interlobular 
stroma and from the adipose tissue within the breast. 
The entire ductal system is lined by epithelial cells,which are surrounded by specialized 
myoepithelial cells that have contractile properties and serve to propel milk formed in the 
lobules toward the nipple. Outside the epithelial and myoepithelial layers, the ducts of 
the breast are surrounded by a continuous basement membrane containing laminin, type 
4 collagen, and proteoglicans. The basement membrane layer is an important boundary in 
differentiating in situ from invasive breast cancer. Continuity of this layer is maintained in 
ductal carcinoma in situ (DCIS), also termed non invasive breast cancer. Invasive breast 
cancer is defined by penetration of the basement membrane by malignant cells invading 
the stroma. 
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4. Pathology Callings 
 
Breast Cysts 
 
Cysts within the breast parenchyma are fluid-filled, epitheliallined cavities that may vary 
in size from microscopic to large palpable masses containing as much as 20 to 30 ml of 
fluid. A palpable cyst develops at least 1 in every 14 women, and 50% of cysts are multiple 
or recurrent. The pathogenesis of cyst formation is not well understood; however, cysts 
appear to arise from destruction and dilation of lobulers and terminal ductules. 
Microscopic studies have shown that fibrosis at or near the lobule, combined with 
continued secretion, results in unfolding of the lobule and expansion of an epithelial lined 
cavity containing fluid. 
Cysts are influenced by ovarian hormones, a fact that explains their variation with the 
menstrual cycle. Most cysts occur in women older than 35 years; the incidence steadily 
increases until menopause and sharply declines thereafter. New cyst formation in older 
women is generally associated with exogenous hormone replacement. 
Intracystic carcinoma is extremely rare. Rosemond has reported that only three cancers 
were identified in more than 3000 cyst aspiration (0.1%). Other investigations have 
confirmed this low incidence. There is no evidence of increased risk for breast cancer 
associates with cyst formation. 
A palpable mass can be confirmed to be a cyst by direct aspiration or ultrasonography. 
Cyst fluid can be straw-colored, opaque, or dark green and may contain debris. Given the 
low risk for malignancy within a cyst, if the mass resolves following aspiration and the cyst 
contents are not grossly bloody, the fluid does not need to be sent for cytologic analysis. 
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If the cyst recurs multiple times (more than twice is a reasonable rule), 
pneumocystography should be performed to evaluate for a sold component and core or 
FNA biopsy should be performed to evaluate the solid elements. Surgical removal of a 
cyst is usually not indicated but may be required if the cyst recurs multiple times, or 
based on the needle biopsy results. 
 
 
Fibroadenoma and Other Benign Tumors 
 
Fibroadenomas are benign solid tumors composed of stromal and epithelial elements. 
Fibroadenoma is the second most common tumor in the breast ( after carcinoma) and is 
the most common tumor in women younger tha 30 years. In contrast to cysts, 
fibroadenomas most often arise in the late teens and in women during their early 
reproductive years. Fibroadenomas are rarely seen as new masses in women after the 
age of 40 or 45 years. Clinically, they present as firm masses that are easily movable and 
may increase in size over a period of several months. They slide easily under the 
examining fingers and may be lobulated or smooth. On excision, fibroadenomas are well 
encapsulated masses that may detach easily from surrounding breast tissue. 
Mammography is of little help in discriminating between cysts and fibroadenomas; 
however, ultrasonography can really distinguish between them because has specific 
characteristics.FNA biopsy can also be used to confirm the imaging findings. 
Fibroadenomas are benign tumors, although neoplasia may develop in the epithelial 
elements within them. Cancer in a newly discovered fibroadenoma is exceedingly rare; 
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50% of neoplasias that involve fibroadenomas are LCIS, 35% are infiltrating carcinomas, 
and 15% are intraductal carcinoma. 
Once a tissue diagnosis confirms that the breast mass is a fibroadenoma, the patient can 
be reassured without the need for surgical excision. If the patient is bothered by the mass 
or it continues to increase in size, the mass can be excised ore treated with cryoablation 
under ultrasonography guidance. The mass may remain palpable following cryoablation 
or, in other cases, the mass may calcify, causing it to feel firmer on palpation. 
Two subtypes of fibroadenoma are recognized. Giant fibroadenoma is a descriptive term 
applied to a fibroadenoma that attains an unusually large size, typically greater than 5 cm. 
the term juvenile fibroadenoma refers to the occasional large fibroadenoma that occurs 
in adolescents and young adults and histologically is more cellular than the usual 
fibroadenoma. Although these lesions may display remarkably rapid growth, surgical 
removal is curative. 
 
Hamartoma and Adenoma 
 
These lesions are benign proliferations of variable amounts of epithelium and stromal 
supporting tissue. A hamartoma is discrete nodule that contains closely packed lobules 
and prominient, ecstatic extralobular ducts. On physical examination, mammaography, 
and gross inspection, a hamartoma is indistinguishable from fibroadenoma. Page and 
Anderson have described an adenoma or tubular adenoma as a benign neoplasm of 
ductules packed clodely together so that they form a sheet of tiny glands without 
supporting stroma. During pregnancy and lactation, these tumors may increase in size, 
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and histologic examination shows secretory differentiation. Biopsy is required to 
estabilish the diagnosis. 
 
Breast Abscesses and Infections 
 
Infections of breast fall into two general categories, lactation infections associated with 
duct ectasia. Lactational infections are thought to arise from entry of bacteria through the 
nipple into the duct system and are characterized by fever, leukocytosis, erythema, and 
tenderness. Infections are most often caused by staphylococcus aereus and may be 
manifested as cellulitis with breast parenchymal inflammation and swelling, termed 
mastitis, or as abscesses. Treatment requires antibiotics and frequent emprying of the 
breast. True abscesses require surgical drainage because they are generally 
multiloculated. 
In women who are not lactating, a chronic relapsing from an infection may develop in the 
subareolar ducts of the breast that is variously known as periductal mastitis or duct 
ectasia. This condition appears to be associated with smoking and diabetes. The 
infections that arise are most often mixed infections that include aerobic and anaerobic 
skin flora. A series of infections which resulting inflammatory changes and scarring may 
lead to retraction or inversion of the nipple, masses in the subareolar area and, 
occasionally,a chronic fistula from the subareolar ducts to the periareolar skin. Palpable 
masses and mammographic changes may result from the infection and scarring; these can 
make surveillance for breast cancer more challenging. 
Subareolar infections may initially be manifested as subareolar pain and mild erythema. If 
treated at this stage, warm soaks and oral antibiotics may be effective. Antibiotic 
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treatment generally requires coverage for aerobic and anaerobic organisms. If an abscess 
has developed, incision and drainage are required, in addition to antibiotics. Repeated 
infections are treated by excision of the entire subareolar duct complex after the acute 
infection has resolved completely, with 4 antibiotic coverage at the same time. Rarely, 
patients will have recurrent infections requiring excision of the nipple and areola. 
A presumed infection of the breast generally cleans promptly and completely with 
antibiotic therapy. If erythema or edema persists, a diagnosis of inflammatory carcinoma 
should be considered. 
 
 
Papillomas and Papillomatosis 
 
Solitary intraductal papillomas are true polyps of epithelial-lined breast ducts. Solitary 
papillomas are most often located close to the areolabut may be present in peripheral 
locations. Most papillomas are smaller than 1 cm but can grow to as large as 4 or 5 cm in 
size. Larger papillomas may appear to arise within a cystic structure, probably 
representing a greatly expanded duct. Papillomas are not associated with an increased 
risk of breast cancer. 
Papillomas located close to the nipple are often accompanied by bloody nipple discharge. 
Less frequently, they are discovered as a palpable mass under the areola or as density 
seen on a mammogram. Treatment is excision through a circumareolar incision. For 
peripheral papillomas, the differential diagnosis is between papilloma and invasive 
papillary carcinoma. 
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It is important to distinguish papillomatosis from solitary or multiple papillomas. 
Papillomatosis refers to epithelial hyperplasia, which commonly occurs in younger 
women or is associated with fibrocystic change. Papillomatosis is not composed of true 
papillomas but has hyperplastic epithelium that may fill individual ducts like true polyp 
but has no stalk of fibrovascular tissue. 
 
Sclerosing Adenosis 
 
Adenosis refers to an increased number of small terminal ductules or acini. It is frequently 
associated with a proliferation of stromal tissue producing a histologic lesion, sclerosing 
adenosis, which can be confused with carcinoma both grossly and histologically. These 
lesions can be associated with deposition of calcium, which can be seen on mammogram 
in a pattern indistinguishable from the microcalcifications of intraductal carcinoma. 
Sclerosing adenosis is the most common pathologic diagnosis in patients undergoing 
needle-directed biopsy of microcalcifications in many series. Sclerosing adenosis is 
frequently listed as one of the component lesions of fibrocystic disease; it is common and 
has no significant malignant potential. 
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Radial Scar 
 
Radial scars belong to a group of abnormalities known as complex sclerosing lesions. They 
can appear similar to carcinomas mammographically because they create irregular 
spiculations in the surrounding stroma. These lesions contain microcysts, epithelial 
hyperplasia, adenosis, and prominent display of central sclerosis. The gross abnormality is 
rarely more than 1 cm in diameter. Lager lesions may form palpable tumors and appear 
as a spiculated mass with prominient architectural distortion on a mammogram. These 
tumors can even result in skin dimpling by producing by producing traction on 
surrounding tissues. They generally require excision to rule out an underlying carcinoma. 
Radial scars are associated with a modestly increased risk for breast cancer. 
 
 
Fat Necrosis 
 
Fat necrosis can mimic cancer by producing a palpable mass or density on a mammogram 
that may contain calcifications. Fat necrosis may follow an episode of trauma to the 
breast or be related to a prior surgical procedure or radiation treatment. The 
calcifications are characteristic of fat necrosis and can often be imaged on 
ultrasonography as well. Histologically, the lesion is composed of lipid-laden 
macrophages, scar tissue, and chronic inflammatory cells. This lesion has no malignant 
potential. 
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Epidemiology 
 
In 2010, a total of 209,060 cases of invasive breast cancer and almost 54010 cases of in 
situ breast cancer were diagnosed in the United States. Breast cancer continues to be the 
second leading cause of cancer related deaths, second to lung cancer, with approximately 
40,000 deaths caused by breast cancer annually. Breast cancer is also a global health 
problem, with more than 1 million cases of breast cancer diagnosed worldwide each year. 
The overall incidence of breast cancer was rising until approximately 1999 because of 
increases in the average life span, lifestyle changes that increase the risk of breast cancer, 
and improved survival from other diseases. The rates began to decrease from 1999 to 
2006 by approximately 2%/year. This decrease has been attributed to a reduction in the 
use of HRT after the initial results of the Women’s Health Initiative were published but 
may also be the result of a reduction in the use of  screening mammography (70.1% of 
women 40 years and older were screened in 2000 versus 66.4% in 2005). Survival rates in 
women with breast cancer have steadily improved over the last decades, with 5-year 
survival rates of 63% in the early 1960s, 75% from 1075 to 1977, 79% from 1984 to 1986 
and 90% from 1995 to 2005. The largest decrease in death rates caused by breast cancer 
has been in women younger than 50 years (3.2%/year ), although they have decreased in 
women older than 50 (2%/year). The decreased mortality from breast cancer is thought 
to be the result of earlier detection via mammographic screening, improvements in 
therapy, and a decreased incidence of breast cancer. The current treatment of breast 
cancer is guided by pathology, staging, and recent insights into breast cancer biology. 
There is an increased emphasis on defining disease biology and status in individual 
patients, with the subsequent tailoring of therapies toward that individual. 
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 Noninvasive breast cancer 
 
 
Noninvasive neoplasms are broadly divided into two major types, LCIS and DCIS. LCIS was 
initially belived to be a malignant lesion, but is now regarded more as a risk factor for the 
development of breast cancer. LCIS is recognized by its conformity to the outline of the 
normal lobule, with expanded and filled acini. DCIS  is a more heterogeneous lesion 
morphologically, and pathologists recognize four broad categories : papillary, cribriform, 
solid, and comedo types. DCIS is recognized as discrete spaces filled with malignant cells, 
usually with a recognizable basal cell layer made up of presumably normal myoepithelial 
cells. The four morphologic categories of DCIS are rarely seen as pure lesions, but in 
reality are often mixed. The papillary and cribriform types of DCIS are generally of lower 
grade and may take a longer period of time to transform to invasive cancer. The solid and 
comedo types of DCIS are generally higher grade lesions. 
As the cells inside the ductal membrane grow, they have a tendency to undergo central 
necrosis, perhaps because the blood supply to these cells is located outside the basement 
membrane. The necrotic debris in the center of the duct undergoes coagulation and 
finally calcifies, thereby leading to the tiny, pleomorphic, and frequently linear forms of 
microcalcifications seen on mammograms. In some patients, aan entire ductal tree may 
be involved in the malignancy, and the mammogram shows typical calcifications from the 
nipple extending posteriorly into the interior of the breast (termed segmental 
calcifications ). For reasons that are not completely understood, DCIS transforms into an 
invasive cancer, usually recapitulating the morphology of the cells inside the duct. There 
is no tendency for the grade to advance with invasion. DCIS frequently coexists with 
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otherwise invasive cancer and, again, the two phases of the malignancy are in step with 
each other morphologically. 
 
Invasive Breast Cancer 
Invasive cancers are recognized by their lack of overall architecture, infiltration of cells 
haphazardly into a variable amount of stroma, or formation of sheets of continuous and 
monotonous cells without respect for from and function of a glandular organ. 
Pathologists broadly divide invasive breast cancer into lobular and ductal histologic types, 
which probably does not reflect histogenesis and only imperfectly predicts clinical 
behavior. Invasive lobular cancer tends to permeate the breast in a single file nature, 
which explains why it remains clinically occult and often escapes detection on 
mammography or physical examination until the extent of the disease is large. Ductal 
cancers tend to grow as a more cohesive mass; they form discrete abnormalities on 
mammograms and are often palpable as a discrete lump in the breast st a smaller size 
compared with lobular cancers. 
Invasive ductal cancer, also known as infiltrating ductal carcinoma, is the most common 
form of breast cancer; it accounts for 50% to 70% of invasive breast cancers. Invasive 
lobular carcinoma accounts for up to 10% of breast cancers, and mixed ductal and lobular 
cancers have been increasingly recognized and described in pathology reports. When 
infiltrating ductal carcinomas take on differential features, they are named according to 
the features that they display. If the infiltrating cells from small glands lined by a single 
row of bland epithelium, they are called infiltrating tubular carcinoma. The infiltrating 
cells may secrete copious amounts of mucin and appear to float in this material. These 
lesions are called mucinous or colloid tumors. Both tubular and mucinous tumors are 
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usually low grade (grade 1) lesions and represent about 2% or 3% each of invasive breast 
carcinomas. 
In contrast, bizarre invasive cells with high grade nuclear features, many mitoses, and lack 
of an in situ component characterize medullary cancer. The malignancy forms sheets of 
cells in an almost syncytial fashion, surrounded by an infiltrate of small mononuclear 
lymphocites. The borders of the tumor push into the surrounding breast rather than 
infiltrate or permeate the stroma. In its pure form, it accounts for only approximately 5% 
of breast cancers; however, some pathologists have described a so called medullay 
variant that has some features of the pure form of cancer. These tumors are uniformly 
high grade, ER and progesterone receptor (PR) negative, and negative for the human 
epidermal grouth factor receptor 2 ( HER-2/neu; HER-2) cell surface receptor. Tumors that 
lack expression of ER, PR and HER-2 are often called triple negative breast cancer. Gene 
expression profiling and microarray analysis of breast cancers have revealed that triple-
negative breast cancers are distinctly different from other ductal breast cancers and may 
also express molecular markers found in basal or myoepithelial cells. The term basal like 
breast cancer describes a specific subtype of breast cancer as defined by microarray 
analysis, whereas triple negative breast cancer is a definition determined by the lack of 
immunohistochemical detection of ER, PR and HER-2. 
The different histologic subtypes of breast cancer have some relationship with prognosis, 
although this is influenced by tumor size, histologic grade, hormone receptor status, HER-
2 status, lymph node status, and other prognostic variables. Infiltrating ductal carcinoma, 
not otherwise determined ( NOS), is the most common form of breast cancer. Its 
prognosis is variable, modified by histologic grade and expression of molecular markers. 
Basal like cancer, or medullary cancer in older classifications, is commonly an aggressive 
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form of breast cancer and, because it triple receptor negative, there are no targeted 
treatments for this form of cancer. Infiltrating lobular breast cancers carry an 
intermediate prognosis, whereas tubular and mucinous cancers have the best overall 
prognosis. These generalizations, based on histologic subtype, are useful only in the 
context of tumor size, grade, and receptor status. Modern classification schemes are 
replacing these older morphologic descriptions with the determination of molecular 
markers and breast cancer subtype by microarray analysis. 
 
Molecular Markers and Breast Cancer Subtypes 
 
There are numerous pathways and molecular markers that have been raported to affect 
breast cancer outcomes, including steroid hormone receptor pathway (ER and PR)  , 
human epidermal growth factor receptor pathway (HER family) , angiogenesis , cell cyle 
(e.g. cyclin-dependent kinases [CDKs]) , apoptosis modulators, proteasome, 
cyclooxygenase-2 (COX-2) , peroxisome proliferator-activated receptor- Y (PPAR-Y) , 
insulin-like growth factors (IGF family) , trasforming growth factors-y (TGF-Y) , patelet-
derived growth factor (PDGF) , and p53. Most these makers are not routinely tested on 
breast cancer specimens at the time of diagnosis nor would it be feaible to do so . 
      Incorporating predictive markers into the routine testing of breast cancers could help 
predict which patients would be most likely to benefit from therapies directed at that 
marker. The best example of this is ER. Before the discovery of ER, all breast cancers were 
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considered potentially sensitive at endocrine therapy. Now, pathologic assessment of ER 
is performed on all primary tumors and predicts which patients should receive therapy 
directed at ER endocrine therapy.  Patients whose tumors are ER negative can be spared 5 
years f endocrine therapy. A second important factor is breast cancer, discovered in 1985, 
is HER-2 or erb-B2/neu protein. This protein is the product of the erb-B2 gene and is 
amplified in approximately 20 % of human breast cancers. The extracellular domain of the 
receptor is present on the surface of breast cancer cells and an intracellular tyrosine 
kinase enzyme links the receptor to the internal machinery of the cell. The tyrosine kinase 
of HER-2 is activated by growth factors binding to partners and cross-stimulating the HER-
2 kinase. Amplification leads to protein overexpression , generally measured clinically by 
immunohistochemistry and scored on a scale from 0 to 3+ .Alternatively
  
, fluorescent in 
situ hybridization (FISH) directly detects the quantity of HER-2 gene copies : there are 
normally two copy numbers. Research has shown that inhibition of the function f the 
HER-2 receptor-like protein slows the growth of HER-2 amplified tumors in laboratory 
models and in clinical trials. Trastuzumab is a humanized antibody directed against the 
extracellular domain of the surface receptor and is effective treatment for HER-2 –
positive breast cancer .HER-2 testing is now a standart part of pathologic reporting on the 
primary tumor and is a predictive marker for HER-2-directed therapies.   
  
A logical classification scheme for invasive breast cancer is based on the expression of ER 
status and HER-2 proteins. It has the advantage of directing different choices. ER- positive 
tumors receive endocrine therapies and HER-2- positive cancers are treated with HER-2 
inhibitors. However, breast cancer is a heterogeneus disease, and different breast cancers 
behave in different ways. For example, some ER-positive tumors are indolent and not life-
threatening, whereas other ER-positive tumors are very aggressive. In an attempt to 
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subclassify the disease further, investigators are turning to global assessment of gene 
expression by using microarrays, these are composed of oligonucleotide probes to almost 
every known expressed sequence of DNA in the human genome. Similar technologies 
based on single-nucleotide polymorphisms (SNPs) in the cancer DNA and profiles of 
expressed proteins are being developed to subclassify cancers and direct treatment. 
An unexpected finding, emphasized recently, is the uniqueness of tumors that are both 
ER- negative and HER-2-negative. These cancers, also negative for PR, are called triple-
negative cancers. They express proteins in common with myoepithelial cells at the base of 
mammary ducts and are also called basal-like cancers. Women who carry a deleterious 
mutation in BRCA1 are much more likely to contract a basal-like cancer that another 
subtype. In summary, categorizing breast cancer according to the expression of molecular 
targets of treatments is practical and appears to agree with nonbiased classifications 
based on gene expression. Classification schemes reflect biology and predict treatment 
efficacy. 
In addition to classification, molecular markers are used to select patients for systematic 
treatment (chemotherapy, endocrine therapy) and to predict the response of patients to 
these pharmacologic treatments. The simplest example is the use of ER or HER-2 status to 
predict the response to endocrine treatment or trastuzumab. Multiple gene products may 
be used I combination for these determinations. Microarray experiments use thousands 
of gene transcripts (mRNAs) to provide a snapshot of an individual cancer s molecular 
phenotype. To adapt this technology for clinical application investigatiors have selected 
critical assemblies of gene product that provides the same predictive ability as a 
nonbiased, genome-wide analysis. The most advanced is a 21-gene test that can be used 
on paraffinembeded tumor material from breast surgical speciments. Originally designed 
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to predict the recurrence of ER-positive, node-negative cancer treated with adjuvant 
endocrine therapy, the 21-gene recurrence score assay provides a recurrence score for 
ER-positive breast cancer that is used clinically to determine whether women with high 
risk ER-positive breast cancer should receive adjuvant chemotherapy in addition to 
tamoxifen. Another multigene assay for determining prognosis is the MammaPrint assay. 
This assay uses fresh tissue prior to formalin fixation and analyses data from 70 genes to 
develop a risk profile. The test provides a simple readout of low risk or high risk disease. 
This tool can be used for risk assessment in patients ER-positive and ER-negative tumors. 
It is likely that tests based on critical combinations of genes will increasingly be used to 
assist clinical decision making when treating breast cancer. 
 
Other tumors of the breast  
Phyllodes tumors 
Tumors of mixed connective tissue and epithelium constitute an important group of 
unusual primary breast tumors. On the end of the spectrum is the benign fibroadenoma, 
which is characterized by a proliferation of connective tissue and a variable component of 
ductal elements that may appear compressed by the swirls of fibroblastic growth. 
Clinically more challenging are the phyllodes tumors, which contain a biphasic 
proliferation of stroma and mammary epithelium. First called cystosarcoma phyllodes, 
the name has been changed to phyllodes tumor in recognition of its usually benign 
course. However, with increasing cellularity, an invasive margin, and sarcomatous 
appearance, these tumors may be classified as malignant tumors. Benign phyllodes 
tumors are recognized as firm lobulated masses that can range a size, with an average 
size of approximately 5 cm. Histologically, these tumors are similar to fibroadenomas, but 
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the whorled stroma forms larger clefts lined by epithelium that resemble clusters to 
leaflike structures. The stroma is more cellular than a fibroadenoma, but the fibroblastic 
cells are bland and mitoses are infrequent. 
Mammographically, these lesions are seen as round densities with smooth borders and 
are indistinguishable from fibroadenomas. Ultrasonography may reveal a discrete 
structure with cystic spaces. The diagnosis is suggested by te larger size, history of rapid 
growth, and occurrence in older patients. Cytologic analysis is unreliable in differentiating 
a low grade phyllodes from a fibroadenoma. Core needle biopsy is preferred, although is 
difficult to classify phyllodes tumors with benign or intermediate malignant potential 
based on a limited sampling. Thus, the final diagnosis is best made by excisional biopsy, 
followed by careful pathologic review. 
Local excision of a benign phyllodes tumor is curative, similar to that for a fibroadenoma. 
The intermediate tumors, are also called borderline, are those in which it is difficult to 
assign a benign label. These tumors are treated by excision, with margins of at least 1 cm 
to prevent local recurrence. Affected patients are at some risk for local recurrence, most 
often within the first 2 years after excision, and close follow up with examination and 
imaging allows early detection of recurrence. Finally, frankly malignant stromal sarcomas 
are at the end of the spectrum. Malignant phyllodes tumors are treated similar to soft 
tissue sarcomas that occur on the trunk or extremities. Complete surgical excision of the 
entire tumor with a margin of normal tissue is advised. When the tumor is large with 
respect to the size of the breast, this may require total mastectomy. Similar to other soft 
tissue sarcomas, regional lymph node dissection is not reuired for staging or locoregional 
control. 
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Metastases from malignant phyllodes tumors occur via haematogeneous spread, 
common sites include lung, bone, abdominal viscera, and mediastinum.  
Angiosarcoma  
This vascular tumor may occur de novo in the breast or within the dermis of the breast 
after irradiation for breast cancer. Angiosarcoma has also been seen to develop in the 
upper extremities of patients with lymphedema, historically after radical mastectomy. 
Angiosarcoma arising in the absence of previous irradiation or surgery generally forms an 
ill-defined mass within the parenchyma of the breast. The differential diagnosis is 
frequently between malignant angiosarcoma and atypical vascular proliferations in 
irradiated skin. Histologically, the tumor is composed of an anastomosing tangle of blood 
vessels in the dermis and superficial subcutaneous fat. The atypical and crowded vessels 
invade through the dermis and superficial subcutaneous fat. These tumors are graded by 
the appearance and behavior of the associated endothelial cells. Pleiomorphic nuclei, 
frequent mitoses, and stacking of the endothelial cells lining neoplastic vessels are 
features seen in higher grade lesions. Rarely seen in hemangiomas, necrosis is common in 
high grade angiosarcomas. Clinically, radiation-induced angiosarcoma is identified as a 
redish brown to purple raised rash within the radiation portals and on the skin of the 
breast. As the disease progresses, tumor protruding from the skin surface can 
predominate. 
Mammography is unrevealing in most cases of angiosarcoma. In the absence of 
metastatic disease at initial evaluation, surgery is performed to secure negative skin 
margins and usually involves a total mastectomy. A split-thickness skin graft or 
myocutaneous flap may be needed to replace a large skin defect created by the resection. 
Metastasis to regional nodes is extraordinarily rare and axillary dissection is not required. 
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Patients remain at high risk for local recurrence after resection of angiosarcoma. For 
patients who present with primary angiosarcoma of the breast, radiotherapy is of benefit 
in the locoregional treatment. Patients with radiation-related angiosarcoma are not 
candidates for further radiotherapy. Metastatic spread occurs hematogenously, most 
commonly to the lungs and bone and less frequently to abdominal viscera, brain, and 
even the controlateral breast. Chemotherapy us generally recommended in the adjuvant 
setting and may improve outcomes of patients with angiosarcoma. For those free of 
metastatic disease at initial evaluation, the median time to recurrence after mastectomy 
is 8 months and the median survival is 2 years.     
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5. Management and lead of breast center 
 
The Breast Centre must have a nominated Clinical lead, a medically qualified doctor from 
any specialty within the team. This person is responsible for ensuring the multidisciplinary 
approach, the full involvement of the breast experts from the core disciplines and their 
regular participation in the MDMs (multi disciplinary meetings), ensuring appropriate 
levels of training and continuing medical education by the team members, breast related 
research activity, performance based on breast cancer quality indicators, data collection, 
etc. 
The Breast Centre must have written clinical protocols, adapted for local use from 
international or national recommendations, including local organizational aspects that 
define the Centre’s requirements for the diagnosis and the management of breast cancer 
at all stages (primary and advanced cancer), up to and including follow up. All protocols 
must be agreed upon by the core team members and should be formally reviewed on an 
annual basis. New protocols and protocol amendments must be discussed and formally 
recorded by the core team at its audit meetings.  
The Breast Centre must have a database for the purpose of monitoring quality indicators 
9
 
and for research. Data that should be recorded in the database are related to: source of 
referral (screening program, spontaneous screening, symptomatic), clinical diagnosis, 
pathological diagnosis, primary treatment and clinical outcomes. Data must include 
information on all primary cancers. It is recommended that Breast Centers also record in 
the database or in a register all surgical operations performed on what is known to be or 
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proves to be benign disease. If breast screening is part of the service, the Centre should 
record whether a case is screen detected or is an interval case (a breast cancer detected 
after a normal screening outcome before the next scheduled screening examination) and 
document this information in the data monitoring system accordingly. The Breast Centre 
must achieve the minimum standards for the mandatory quality indicators as defined by 
EUSOMA.  
The Breast Centre must hold at least weekly a multidisciplinary case management 
meeting (MDM) to discuss diagnostic preoperative and postoperative cases, as well as 
any other issue related to breast cancer patients, which requires multidisciplinary 
discussion 
10
(it is chosen a fixed day each week at which all members of the core staff are 
present and discuss cases , in Capa Istanbul University Clinique the meeting was chosen to 
be on Friday of every week where a presentation was earlier in the week prepared with 
all cases and diagnosis, prognosis and follow up was discussed by all the members, also 
university students were allowed to participate in order to understand better the 
teqniques and the approached they see in Clinique ). The Breast Centre must discuss at 
least 90% of all breast cancer cases MDM. All cases with needle or surgical biopsy and 
those cases without a definitive diagnosis must be discussed prospectively before any 
treatment is given. The pre-operative MDM should consider three key components that 
influence decision making: patient-related factors, tumor related factor, treatment 
options
11
. At the discussion of pre-operative breast cancer cases, the following team 
members must be present: radiologist, pathologist, medical oncologist, 
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surgeon/oncoplastic surgeon, breast care nurse, and radiation oncologist. At the 
discussion of post-operative cases, the following core team members must be present: 
pathologist, surgeon, medical oncologist, radiation oncologist and breast nurse. The other 
team members should be encouraged to attend and, in any case, should be reachable for 
consultation.  
After decisions are made dealing with patients, informing and supporting them is another 
important point a breast center must provide in a proper way. 
It is recommended that the diagnosis is given to the patient as soon as possible. A 
preliminary communication on the diagnosis can be given to the patient by each specialist 
according to their competence. Following the appropriate MDM discussion to confirm the 
diagnosis and plan the treatment the results should be given to the patient by the 
clinician who will take primary responsibility for providing this treatment to this patient. A 
breast care nurse must be available to discuss fully with the patient the options for 
treatment and to give emotional support. A suitable room with sufficient privacy should 
be available. Each patient has to be fully informed about each step in the diagnostic and 
therapeutic pathway and must be given adequate time to consider the options and make 
an informed decision. 
 A diagnosis of breast cancer must not be given to a patient by letter or on the telephone, 
unless at the specific request of the patient in exceptional circumstances, given adequate 
and fully informed choice. 
 Patients should commence the primary treatment within 4 weeks from the definitive 
diagnosis or from the first consultation at the Breast Centre if diagnosed. Women must be 
offered clear verbal and written information (leaflets) that describes the diagnostic and 
treatment options. It is recommended that these leaflets are developed by, and 
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personalized for, the Breast Centre. The Breast Centre should also provide written 
information concerning local outpatient support groups and advocacy organizations. It is 
recommended that patients are provided with a list of their rights as outlined in the 
breast cancer resolution of the European Parliament.  
The Breast Centre should provide teaching, whether for junior staff members or students, 
on a national or international basis (there may be university students during internship or 
Erasmus student from different countries of Europe longing to see different approaches 
to medicine).  
Some Breast Centers may particularly concentrate on certain areas (e.g.) reconstruction, 
screening, pathology, etc. The Breast Centre should organize at least one teaching course 
per year at local, regional or national level. Research is one of the essential parts of 
training specialists
12
.  
Breast Centers are encouraged to be involved in translational research. The Breast Centre 
should record the numbers of patients participating in clinical trials and collect details of 
any other research activities, such as evaluation of newly introduced techniques. The 
Breast Centre should aim to enroll at least 10% of all patients into clinical trials, assuming 
fully informed patient choice. 
Sometimes a breast center is found in situations to rely on dedicated clinics to guarantee 
a complete cover of disciplines and specialists. 
Dedicated clinics run by Breast Centre core team members guarantee patients continuity 
of care. All consultations for breast disease must be done in dedicated clinics, i.e. new 
patient clinics, advanced patient clinics and follow up clinics must be separate, i.e. to each 
of them a specific slot of time and location must be assigned. It is desirable that the 
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Breast Centre is able to offer advice with regard to dietary, nutrition and complementary 
medicine. 
The Breast Centre must have a dedicated clinical geneticist responsible for the clinical 
genetics clinic. 
Advice from other specialists, such as breast and reconstructive surgeon, breast 
radiologist, gynecologist and psychologist may be required. The clinical geneticist, if 
necessary, has to ensure immediate consultation with the other Breast Centre team 
members. Breast Centers that are not running a genetic service must have in place an 
agreement with a hospital where this service is available. Close interaction between the 
Breast Centre and the genetics service is required to ensure continuity of care. 
The patient data from these clinics should be formally recorded in an appropriate 
database and this team should be actively involved in research. 
Genetic testing (for Breast Cancer - BRCA mutation) must be available when required and 
a molecular geneticist should be accessible for consultation by the specialists in the clinic. 
Risk assessment counseling and DNA testing for BRCA mutations in a selected high risk 
group should be offered, in accordance with unit protocols. 
The clinical genetics service should offer: 
Genetic analysis: Genetic testing should include complete sequencing of coding regions, 
either directly or after a screening method. Specific techniques to detect duplications or 
deletions of one or more exons may be indicated. 
Diagnostic Surveillance: The Breast Centre should have written protocols where 
diagnostic surveillance is specially considered for high risk women including screening 
MRI according to the level of risk. 
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Other intervention: The Breast Centre should have a written protocol for prophylactic 
operations and chemoprevention.  
Psychological support should be available and given to patients when necessary to 
support them through their assimilation with their genetic risk and to support their 
individual decision making. Women referred after screening or with symptoms that are 
possibly related to breast cancer should be seen within maximum 3 or 4 calendar days. 
Clinics to which patients are referred or self-referred must be staffed by a surgeon (or 
equivalent clinician) or a radiologist from the breast care team. Multidisciplinary working 
should allow all standard investigations for triple assessment (clinical examination and all 
appropriate imaging and tissue diagnostic procedures) to be completed at one visit. 
Advanced breast cancer patients must be seen within the Breast Centre. These clinics 
must be separate from the general oncology clinics and attended by a medical oncologist 
and/or a radiation oncologist. The surgeon should be available on request.  
The Breast Centre should offer the possibility to the patient to consult the different 
specialists in the Breast Centre for a second opinion. If a patient requests an external 
second-opinion this should be facilitated. 
A nominated clinical psychologist (psycho-oncologist) with special experience in seeing 
breast patients must be available at the Breast Centre. 
If the patient is experiencing psychological morbidity that cannot be dealt with effectively 
by members (usually breast care nurse or psycho-oncologist) of the Breast Centre team, 
she should be referred to a psychiatrist with whom particular arrangements to see breast 
patients for the Breast Centre are made. Regular support (advice, counseling and 
psychological help) is given by breast care nurses and psychologically professionally 
trained persons with expertise in breast cancer. 
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Follow up should be done within the Breast Centre by members of the Breast Centre core 
team, according to the local organization and patient wish. 
The Breast Centre should offer the possibility to precede with all necessary imaging 
investigation procedures at the same visit. 
The Breast Centre must give advice and support to the patient with symptoms and 
complaints due to hormonal therapy (ex: osteoporosis, gynaecological problems, etc.) 
referring the patient to the specific health care giver depending on the problem. 
If the follow up is not carried out by the Breast Centre, the Centre should collect 
information at least yearly and include these data in the Breast Centre’s database. 
There should be a prosthesis fitting service within the centre or referral to a service 
outside the hospital should be given to the patient. 
There must be an identified physiotherapist, lymphatic drainage specialist or a breast care 
nurse for the treatment of lymphoedema and its related sequelae. Physiotherapy, and if 
necessary, lymphatic drainage therapy must be available for the postoperative recovery 
period to ensure a good shoulder mobility. 
A dedicated revalidation program for cancer patients who require assistance in the 
recovery of functional status after treatment should be available. 
The Breast Centre must have access to a nuclear medicine service where specialists take 
care of all the procedures and examinations relevant in breast cancer care. 
The Breast Centre must be able to treat patients with advanced breast cancer including 
loco-regional recurrences and metastatic disease, offering treatments according to 
multidisciplinary competencies, as this significantly improves quality of life. 
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With regard to end of life care the Breast Centre must ensure that a high quality palliative 
care service is available and, if possible, links with the local network for home assistance 
(ex. hospices, home care organizations, etc.). 
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6. Members of a Breast Center 
After this short panoramic representation of breast cancer I would like to describe in 
details all the members of a high quality diagnostic Breast Center. 
As I previously sad, documented on EUSOMA guidelines, a breast center is composed of a 
large group of specialized physicians, and not only, that come together with the aim of 
giving the best treatment and support to a breast cancer affected patient. 
All core team members should comply with the recommendations and standards defined 
in the EUSOMA guidelines for specialized Health Professionals
13
. 
Radiographers: Only radiographers with a special training in breast diagnosis should be 
allowed to perform mammography. The Unit must have at least 2 dedicated 
radiographers, each performing at least 1000 mammograms per year
14
. The 
radiographers should also attend refresher courses at least every 3 years. 
The Breast Centre must have protocols detailing how the periodical review of the 
technical performance of the radiographers is carried out. Radiographers should 
participate in regular audits of their technical performance. Breast Centre using either 
analogue film/screen mammography, Computed Radiography mammography (CR 
mammography) or full digital mammography must have protocols on how to carry out 
quality control on a daily basis and should follow the guidelines on equipment quality 
control as detailed in the European Guidelines. 
Mammograms should be performed by suitably trained and experienced radiographic 
staff fulfilling all necessary training and working professional requirements and holding 
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any relevant Certificate of Competence as previously described. In Units where no 
mammographically certificated radiographer is employed, the member of staff 
performing the mammograms must have undergone full training in the radiographic 
aspects of mammography, comply with all requirements as laid down for radiographic 
staff, including any necessary external quality assessment schemes and update courses 
and take the lead in regular radiographic quality control procedures. For the purpose of 
this document such a person will be referred to as the radiographer.  
It is the radiographer’s responsibility within the team to produce an optimum image with 
regard to positioning and technical aspects and in a manner acceptable to women. All 
obvious clinical abnormalities including the presence of a palpable lump felt by the 
radiographer during mammographic positioning, obvious distortion, skin abrasions and 
other significant cutaneous abnormalities should be recorded and this information made 
available for the radiologist at the time of film reading. The radiographer must inform the 
woman about the procedure, how it is to be performed, how she will get her result, and 
in what time scale. The radiographer in charge of the unit is responsible for ensuring that 
a regular quality control program is carried out and is responsible for reporting breaches 
of quality to the radiologist in charge.  
In order to limit unnecessary exposure to ionizing radiation and the creation of 
unnecessary anxiety, the technical retake level where repeat mammograms are necessary 
for positioning or technical faults must be kept to an absolute minimum, preferably below 
1% but no more than 3%. All such retakes should be documented for audit purposes. 
Positioning performance requirements for adequate mammographic examinations are 
laid out in chapter 3 of the 4
th 
edition of the European guidelines for quality assurance in 
breast cancer screening and diagnosis and must be adhered to. The minimum 
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requirements for positioning of the standard lateral oblique projection are that the 
pectoral muscle must be displayed down to nipple level, the inframammary fold should 
be visible and the nipple should be in profile. Skin folds, movement and other artifacts 
should be absent. An external quality assessment scheme should be in place so that peer 
review of adequate positioning is performed and satisfactory results obtained in at least 
97% of images. All films must be appropriately named, dated and marked correctly for 
side.  
In order to maintain the skills and expertise required to carry out optimum 
mammography and be a useful member of the multidisciplinary team, the radiographer 
must be involved in performing at least 20 mammographic studies per week, preferably 
more. 
Radiological staff  
The radiologist must be specifically trained and experienced in breast imaging. This 
should include a knowledge of technical requirements of mammography equipment, 
processing, exposure factors and all those other factors of importance that are necessary 
in the production of good image quality. If possible, radiologists involved in symptomatic 
activity should also participate in local screening programs both for the reading of 
screening films and the assessment of screen-detected abnormalities.  
A dedicated mammographic film viewer must be available and films should be read in a 
suitable room with control of background lighting. This is even more crucial for the 
reading of digital examinations on soft copy due to the lower light output of monitors 
compared to light boxes for analogue films. It is the responsibility of the radiologist to 
ensure that the mammograms are of adequate diagnostic standard, particularly with 
regard to positioning and film density. Where films are inadequate, they must be 
 Management of a High Quality Comprehensive Breast Center 
46 
 
repeated. The radiologist must also ensure that feedback is provided to the radiographer 
on image quality. The report provided by the radiologist must state quite clearly the 
nature of any abnormality present, its side, site, size, description and extent. The 
radiologist should make clear the implication of the imaging findings and should 
recommend the most suitable necessary further investigation or sampling procedure.  
If a significant finding is present, carrying a high risk of malignancy, it is the responsibility 
of the reporting radiologist to ensure that the woman is aware that further investigation 
or management will be required. For this reason it is recommended that wherever 
possible the radiologist should be available within the unit during the mammographic 
examination so that any necessary procedure such as an ultrasound can be performed 
while the woman is still present. This will avoid the need for a separate return visit, and 
allow the radiologist to pass on any necessary information to the woman, with due regard 
paid to the importance of not creating unnecessary anxiety. Under such circumstances it 
is obviously beneficial if nurse counseling is available at that time. 
 
 
Breast surgery and reconstructive surgery (oncoplastic surgery) 
The Breast Centre must have at least two dedicated breast surgeons. 
In the Breast Centre all surgeons (general, reconstructive or gynecologist) operating on 
breast pathology must be dedicated and specially trained in breast surgery. To be 
considered a breast specialist the surgeon must spend at least 50% of his/her working 
time in breast disease. This 50% has to be calculated on the basis of the standard weekly 
full working time as defined in the national collective agreement on working times. To be 
considered a specialist breast surgeon and a member of the core team, each surgeon of 
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the Breast Centre must personally carry out the primary surgery on at least 50 newly 
diagnosed cancers per annum
15
. If the Breast Centre has breast surgeons in training, 
those breast surgeons responsible for supervising the trainees during surgical procedures 
might perform less than 50 primary cases as first operator. In this case official 
documentation on their role as second operator supervising the trainee must be 
available. The increasing demand for reconstructive procedures has fostered the 
development of oncoplastic surgery, i.e. the combination between plastic and oncology 
surgery, to obtain a good aesthetic result and optimizing oncologic outcomes
16
. 
Oncoplastic techniques for breast reconstruction are becoming a new standard of care in 
the management of breast cancer patients
17
. The breast surgeons in the team should be 
able to undertake basic reconstruction, when required, and oncoplastic surgery. 
Breast pathology specialist 
The Breast Centre must have at least two dedicated breast pathologists (one of whom 
should be nominated as the breast pathology lead for the team). To be considered a 
breast specialist, the lead pathologist must spend 50% of his/her working time in breast 
disease and the other dedicated pathologists at least 25%. This 25% and 50% has to be 
calculated on the basis of the standard weekly full working time as defined in the national 
collective agreement on working times. The specialist breast pathologists should be 
responsible for all breast pathology and cytology dealt with by the Breast Centre. 
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All specialist pathologists reporting breast cancer must report on at least 50 primary 
breast cancer resections per year
18
. 
The dedicated breast pathologists should take part in regional, national or European 
breast cancer reporting quality assurance schemes. Breast pathologists should be familiar 
with their national and/or European performance quality standards and guidelines. 
 Breast medical oncologist 
The Breast Centre must have at least two medical oncologists dedicated to breast cancer. 
To be considered a breast specialist, the medical oncologist must spend 50% of his/her 
working time in breast cancer. This 50% has to be calculated on the basis of the standard 
weekly full working time as defined in the national collective agreement on working 
times. 
Supervision of systemic therapy and or decision making process for adjuvant and 
neoadjuvant treatments has to be supervised by the dedicated medical oncologists. 
If medical oncology Unit is not available within the hospital, the Breast Centre must have 
an agreement with a medical oncology unit and the medical oncologist must attend 
MDMs at the Breast Centre. Outcome information on all patients treated with systemic 
therapy should be collected, even if patients are treated outside the Breast Centre. 
Breast radiation oncologist 
The Breast Centre must have at least two radiation oncologists dedicated to breast 
cancer. 
To be considered a breast specialist, the radiation oncologist must spend at least 40% of 
his/her working time in breast disease. This 40% has to be calculated on the basis of the 
                                                           
18
 National Coordinating group for breast screening pathology. Guidelines for breast pathology services. 
NHSBSP Publications; 1999. 
 Management of a High Quality Comprehensive Breast Center 
49 
 
standard weekly full working time as defined in the national collective agreement on 
working times. 
Experience in special techniques such as forward planned dose homogenization 
(Intensity-Modulated Radiation Therapy –IMRT like), partial breast irradiation, treatment 
under respiratory control and 3D brachytherapy is recommended. 
If the radiation oncology unit is not available within the hospital, the Breast Centre must 
have an agreement with a radiation oncology unit and the radiation oncologist must 
attend MDMs at the Breast Centre. Outcome information on all patients treated with a 
radiation therapy should be collected, even if patients are treated outside the Breast 
Centre. 
Breast care nursing 
At least two breast care nurses are needed per Breast Centre. To be considered a breast 
specialist, the nurse must be dedicated full time to breast disease. Full time is calculated 
on the basis of the standard weekly full working time as defined in the national collective 
agreement on working times. Breast care nurses must attend the MDMs. Breast care 
nurses must be available throughout the patient pathway from the diagnosis through 
treatment and follow up, to offer practical advice, emotional support, further explanation 
with regard to treatment plan and educational information on side-effects
19
. 
Breast care nurses must be available at the time of communication of diagnosis and in 
case of communication of recurrent or advanced disease. For this purpose the breast 
nurse must be present during the clinic or must meet the patient immediately afterwards 
or however maximum of one week after diagnosis. Breast care nurses should also be 
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available at follow up clinics. Breast care nurses must be involved in the development of 
protocols, patient pathways and information material. 
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7. Departments of a Breast Center 
As I previously mentioned the breast unit can be whether a multi-departmental center 
established in the same building or not very distantly located departments who have 
agreed to follow and treat the breast cancer affected patients according to the European 
protocols. 
Breast radiology 
The Breast Centre must have at least two dedicated breast radiologists. To be considered 
a breast specialist each radiologist of the Breast Centre must spend at least 30% of his/ 
her working time in breast imaging. This 30% has to be calculated on the basis of the 
standard weekly full working time as defined in the national collective agreement on 
working times. 
Where possible radiologists involved in the assessment of breast patients should 
participate in both breast screening and the imaging of symptomatic breast problems. 
They should participate in the related national or regional radiology quality assurance 
schemes. Each breast radiologist working in the Breast Centre must read a minimum of 
1000 mammography cases per year (5000 cases per year for those participating in a 
screening program)
20
. Double reading of mammograms should be encouraged for both 
screening and symptomatic mammography when the mammogram workload is less than 
3000 per year. With regard to patients referred from outside the Breast Centre, the 
outside mammograms should be reviewed by the Breast Centre radiologists. Each 
radiologist must attend at least one diagnostic clinic per week for symptomatic patients 
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or breast screening recall further assessment. The Breast Centre must have all the 
necessary imaging equipment for complete and adequate breast diagnosis: 
Mammography Unit (preferable digital) 
Stereotactic biopsy attachment and/or dedicated prone biopsy table 
Ultrasound equipped with a small parts probe ≥10 MHz 
It is recommended that this equipment is not older than 10 years, unless carefully 
maintained and complying with national and/or international standards. 
Quality control of all equipment used for breast imaging must be routinely performed, 
according to the relevant national protocols and/or the European Guidelines. 
The Unit must be able to perform the following examinations: 
Clinical examination 
Mammography 
Ultrasound of the breast and axilla 
Core biopsy – free-hand, ultrasound guided and X-ray guided. (If this is not available 
within the Breast Centre there must be a formal agreement with a local diagnostic 
service). 
Breast MRI (If not available within the hospital, the Unit must have an agreement with a 
local diagnostic service that provides breast MRI). 
Non-surgical diagnosis by needle biopsy of both benign and malignant disease is the 
expected standard. 
Primary diagnosis using open surgical biopsy must be considered exceptional. 
Core biopsy (CB) is considered to be the preferred technique for sampling the breast. 
Fine Needle Aspiration Cytology (FNAC) is the technique primarily used for sampling 
axillary lymph nodes. 
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The Breast Centre is also encouraged to perform vacuum assisted biopsy (VAB) under 
ultrasound, X-ray or MRI guidance. 
The Breast Centre must use a single formal imaging risk classification (e.g. BIRADSe or the 
European Classification).  
 
Surgery  
The Breast Centre must make arrangements with one or two nominated reconstructive 
surgeons with a special interest in breast reconstructive and reshaping techniques. 
At the Breast Centre sentinel lymph node biopsy procedures must be available. 
The Breast Centre should also advise and where necessary treat women with benign 
disease, e.g. cysts, fibroadenoma, mastalgia, inflammatory conditions, etc. 
 
Pathology  
The pathology laboratory must be equipped with: microscopes, cryocut histoprocessors, 
microtome staining machines and immunostainers. The equipment should be replaced 
every 10 years unless carefully maintained and complying with national and/or 
international standards. With regard to workup of the specimen, items included in the 
report, nomenclature, special studies (immunohistochemistry for diagnosis, 
immunohistochemistry for oestrogen receptor +/– progesterone receptor and access to 
HER2/neu testing), the dedicated breast pathologists should fulfill the requirements set 
by the European Guidelines
21
. For reporting core biopsies the unit must use the B-
classification as described in the European Guidelines. Double reading of biopsies is 
encouraged. It is recommended that the Breast Centre has the ability to show the 
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histology of special cases at the MDM, preferably from slides (videomicroscope or 
scanned slide) to support the understanding of difficult histopathological reports. The 
pathology laboratory must archive slides, blocks and histopathological reports following 
the relevant national guidance but, as a minimum, for over 20 years slides and blocks and 
reports for 30 years. 
 
Radiation Oncology 
The minimum equipment in a radiation oncology unit must include at least two 
megavoltage units, a simulator (preferably a computed tomography simulator) and a 
computerized 3D planning system. The radiation oncology unit must have a quality 
assurance program for the entire process, including for the machines/infrastructure. If 
specific equipment or working procedures are in place for treating breast cancer patients, 
this has to be included in the quality assurance program. 
The radiation oncology unit must comply with national protocols with regard to quality 
assurance. Radiotherapy planning must be done according to optimized, preferably 3D, 
procedures (using tools such as dose volume histograms) taking into account predefined 
constraints for organs at risk (including as a minimum heart and lungs). 
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8. Diagnostic guidelines of breast cancer 
 
Since 1990, in United States and many European countries, breast cancer mortality is 
decreasing by 1–2% per year, thanks to early detection and improved treatment. 
Breast cancer care is complex, onerous and expensive, therefore quality measurements 
are essential to monitor effectiveness and to guide improvements in healthcare. It has 
been reported that in Europe there were still wide differences in treatment offered to 
patients with breast cancer in terms of mastectomy and radiotherapy rates and use of 
adjuvant chemotherapy and hormone therapy. It has also been shown that the 
specialized breast cancer care was associated with a significant reduction in mortality. 
The European Parliament Resolution on Breast Cancer calls on Member States to ‘Ensure 
nationwide provision of interdisciplinary breast units in accordance with the EU guidelines 
by 2016 since treatment in an interdisciplinary breast unit has been proved to raise 
chances of survival and to improve the quality of life, and calls on the Commission to 
deliver a progress report on this every two years’. In accordance with this resolution, the 
European Society of breast cancer specialists – EUSOMA has started a voluntary 
certification process to assess the clinical performance in breast cancer care in dedicated 
Europeans units. So far, 32 breast units have been recognized to comply with the 
requirements requested by EUSOMA and other EU Guidelines on the basis of information 
collected by a questionnaire and by a site visit carried out by an independent team of 
breast cancer care experts. It is therefore necessary to define a set of quality indicators 
that should be routinely measured and evaluated in order to confirm that the clinical 
outcome reaches the requested standards. With this aim, a workshop was organized in 
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Milan from 23rd–24th June 2008 during which 24 experts from different disciplines have 
reviewed the international literature and selected the main process and outcome 
indicators available for quality assurance of breast cancer care. 
In order to identify appropriate indicators for breast cancer healthcare quality assurance, 
according to national and international guidelines, a review of the literature for evidence 
based recommendations has been performed by the steering committee. Twenty-eight 
selected papers and documents were sent, well before the EUSOMA workshop, to the 
experts invited to prepare this consensus paper. Experts met in June 2008, with an initial 
and a final plenary discussion of about 3 hours each and with a separated discussion in 
four panel groups (diagnosis, surgery and loco-regional treatment, systemic treatment 
and staging). Each expert panel selected and defined a core set of indicators, taking into 
account the evidence-based effect on outcome of the items they are related to. As stated 
in the Agency for Healthcare Research and Quality (AHRQ) Evidence Report, no. 105 04-
E030-2, 2004, the key properties of a quality measure taken into consideration were 
reliability, meaning that the observation is highly consistent whenever measured, by the 
same observer at different points or by different observers, and validity, which means 
that the indicator is really measuring what it is intended to do. Two additional properties 
were of concern for selecting the most appropriate quality indicators: usability, that 
means the observations generated by the measured application are easily interpretable in 
order to prompt actions concerning healthcare delivery, and feasibility, that requires easy 
data collections during routine clinical activities with limited related costs. Expert panels 
were requested, whenever possible, to select both process and outcome measures, 
simply and clearly defined. Considering the certification process setting, quality indicators 
were restricted to a minimum, reflecting the whole diagnostic and therapeutic process 
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and requiring readily available and systematically collected variables to be calculated. For 
each indicator was reported: 
(1) The definition 
(2) The minimum and target standard 
(3) The motivation for selection 
(4) The level of evidence 
The level of evidence is defined as the probability that the quality indicator is based on 
sound evidence (well designed and conducted studies). The level of evidence has been 
graded according to the short version of the US Agency for Healthcare Research and 
Quality classification, as follows: 
Level of evidence 
(I)  Requires at least a randomized clinical trial (RCT) as part of the body of the literature – 
overall of good quality and consistency – which supports the clinical recommendation 
(quality indicator) 
(II)  Requires well-designed quasi-experimental clinical studies, but not RCT 
(III)  Requires well designed descriptive studies 
(IV)  Expert judgment. This implies the absence of good quality clinical studies on the relevant 
matter 
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9. Breast Assessment Unit  
The breast assessment unit is a smaller format of a breast center based on the same 
quality controls and the same protocols and European requirements. While a breast 
center must offer to its patients a global care, the basic assessment unit provides the first 
but complete formula to allow a high quality diagnosis and further treatment. It can be an 
independent entity or part of a specialized and high quality comprehensive breast center. 
While basic diagnostic imaging in the form of mammography/ultrasound may be 
sufficient for many women, those with significant symptoms, clinical findings, or 
mammographic findings need further workup which will require more specialist 
equipment and staff. A protocol should be in place with referring General Practitioners so 
that women with a clinical finding carrying a significant risk of malignancy should be 
referred directly for assessment at a specialist breast unit. Such clinical findings will 
include a discrete new palpable mass, nipple discharge – particularly if single duct and 
unilateral, nipple retraction, nipple eczema, skin distortion such as tethering, dimpling or 
a change in breast shape, palpable axillary lymphadenopathy or inflammatory change. In 
this setting the woman will undergo a process of triple assessment i.e. clinical, imaging 
and cytological/histological investigation, performed by a specialist multidisciplinary team 
with access to more sophisticated imaging equipment and non-operative diagnostic 
techniques.  
Breast assessment units which are not functioning as part of a specialist breast unit must 
have written protocols available for triple assessment techniques. Additional 
mammographic techniques must include the ability to perform paddle compression and 
microfocus magnification views. Image guided sampling techniques must be available 
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with the ability to perform these either under ultrasound or stereotactic control. If 
abnormalities are visible sonographically, it is more suitable for sampling to be performed 
under ultrasound control. It is generally advisable for image guided sampling to be 
performed for any solid sonographically detected lesion. If required, microcalcification 
may occasionally be sampled under ultrasound control, but more usually stereotactic 
procedures will be required. For audit and documentation purposes, any image-guided 
sampling procedure should have at least one recorded image showing accuracy of needle 
placement.  
Sampling techniques may include fine needle aspiration cytology, core biopsy or vacuum-
assisted biopsy techniques, the use of which will depend upon the local radiological and 
cytological expertise, and audit of results obtained. In expert hands, FNAC still has a role 
and can allow immediate cytology reporting or checking for adequacy of cellularity.  
Core biopsy can provide increased sensitivity and specificity compared to fine needle 
aspiration cytology. Core biopsy is preferred for lesions of architectural distortion and 
microcalcifications, and may also allow definitive diagnosis of a benign lesion which will 
then not require surgical excision biopsy. If core biopsy is performed for microcalcification 
it is essential that specimen radiography of the cores be obtained to demonstrate the 
presence of calcification.  
Sampling techniques should be carried out with due regard to the imaging or clinical 
modality carrying the most suspicious features. Where there is a possibility of discordant 
clinical and imaging findings with regard to any lesion, it is advisable to carry out sampling 
under both imaging and clinical guidance. Very occasionally there may remain a 
significant discordance between suspicious radiological features and benign sampling 
where no reasonable pathological correlation can be made, following case discussion 
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between the radiologist and pathologist. Under these circumstances, open surgical 
excision is advisable.  
It is regarded as good practice that lesions which are predominantly architectural 
distortion should be subject to excision biopsy following pre-operative diagnostic workup 
due to a significant risk of associated malignancy which may not be demonstrated even 
under ideal sampling conditions. Recent work however has shown that it may be safe to 
leave radial scars in place providing sufficient material has been obtained – at least 12 
core samples. Also lesions that are proven to contain atypical ductal hyperplasia should 
be subject to excision due to the risk of associated malignancy.  
Where resources allow, vacuum-assisted biopsy techniques offer significant advantages 
for biopsy in a proportion of patients in achieving definitive pre-operative diagnosis and 
reducing the need for surgical intervention. This technique can provide greater tissue 
volume for histological analysis with less risk of epithelial displacement or 
underestimation of disease such as DCIS or invasive tumors. It can also be used for 
excision of benign lesions. Where resources are scarce, it should be borne in mind that 
the disposable elements of FNAC are approximately 1 Euro compared to core biopsy, 20 
Euros, and vacuum-assisted biopsy technique, 300 Euros. Costs of time and number of 
staff involved in performance of the procedure, and non-disposable equipment costs 
must also be considered and balanced with the true benefit of the procedure in relation 
to subsequent patient management.  
Radiographic, radiological and histo/cytopathological staff must be fully conversant with 
the accurate carrying out and interpretation of all these procedures. Specific standards of 
performance in sampling procedures must be adhered to, particularly with regard to 
insufficiency of results and non-operative diagnosis 
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Basic requirements for a Breast Assessment Unit  
In addition to the standards achieved by the Diagnostic Mammography Unit, a centralized 
system of diagnostic assessment for mammographically or clinically detected lesions must 
be available. There should be a full range of assessment facilities provided in order to 
allow complete and adequate work up by the Unit without necessarily having to refer the 
woman on for further investigation elsewhere.  
The Breast Assessment Unit should:  
A. Perform at least 2,000 mammograms a year.  
B. Be able to perform physical examinations and ultrasound examinations as well as the full 
range of radiographic procedures. Provide cytological examination and/or core biopsy 
sampling under radiological or sonographic guidance.  
C. Employ a trained radiologist reading at least 1,000 mammograms a year.  
D. Have organized and specialist cytological and histopathological support services.  
E. Participate in multidisciplinary communication and review meetings with others 
responsible for diagnostic and treatment services.  
F. Monitor data and feedback of results.  
G. Keep a formal record of the assessment process and outcomes. 
The requirements placed upon a breast assessment centre as part of a specialist breast unit 
may be even more rigorous than these. 
 
Targets (radiological) 
Technical repeat rate minimum level <3% - expected <1% 
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More than 97% of women will have an acceptable examination according to the 
positioning and exposure criteria given.  
100% of women will be informed by the radiographer of the method and timescale for 
receiving her results.  
Minimum 20 mammographic studies per week must be performed by each radiographer.  
Basic quality control  
The following is a basic summary of routine quality control tests to be performed by the 
radiographer: 
Daily Analogue Tests  
Mechanical, safety and function checks  
Standard density consistency tests  
Reproducibility of mAs values  
Sensitometry  
Clean x-ray cross over rollers  
Screen inspection and cleaning  
Cassette inspection for wear and tear  
Daily Digital Tests  
Monitor check  
Weekly Analogue Tests  
Automatic exposure control check  
Image quality  
Weekly Digital Tests  
Homogeneity (image quality) check  
3-6 monthly tests (performed by radiographer or physicist)  
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Sensitivity and radiation absorption of cassettes  
Film screen contact  
Calibration of densitometer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Management of a High Quality Comprehensive Breast Center 
64 
 
10. Quality indicators on diagnosis 
 
Breast cancer care is complex, onerous and expensive, therefore quality measurements 
are essential to monitor effectiveness and to guide improvements in health care. From 
this necessity derives the need of these quality indicators that are needed to be taken in 
consideration from each breast center in order to optimize the results and the costs to 
reach the targets. 
 
1.  Completeness of clinical and imaging diagnostic work-up 
Definition: Proportion of women with breast cancer who preoperatively underwent: 
• Mammography 
• Physical examination 
• Ultrasound 
Minimum standard: >90% 
Target: >95% 
Motivation: To allow a proper triple diagnostic approach and to identify size, site and 
possible multifocal and/or controlateral disease. Axillary ultrasound (possibly separately 
recorded) and controlateral breast examination (mammography and physical) are 
included.  
Level of evidence: III Several studies have shown an increase of accuracy by the 
combination of different diagnostic tests. 
                     
2.  Specificity of diagnostic procedures (B/M ratio) 
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Definition: Ratio of benign to malignant diagnoses is based on definitive pathology report 
(surgery only, non-operative biopsies excluded). 
Minimum standard: 1:2 
Target: 1:4 
Motivation: To minimize unnecessary operations for benign conditions 
Level of evidence: III according to NA and NHS guidelines based on the literature evidence 
on the follow-up of non-operated lesions, which are not at risk of developing cancer. 
 
3. Pre-operative diagnosis 
Definition: The proportion of women with breast cancer (invasive or in situ) who had a 
pre-operative definitive diagnosis (B5 or C5). 
Minimum standard: 80% 
Target: 90% 
Motivation: To reduce the number of unnecessary operations, to plan complete 
assessment and treatment, and for patient counseling 
Level of evidence: III 
 
4. Completeness of prognostic/predictive characterization 
4a Definition: The proportion of invasive cancer cases for which the following 
prognostic/predictive parameters have been recorded: 
• Histological type 
• Grading (according to EU Guidelines) 
• ER & PgR 
• HER 2 
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Minimum standard: >90% 
Target: >95% 
Motivation: Histological type and grade have not only been a prognostic influence but 
also a predictive value for multifocality and metastatic pattern and are part of the core 
data set on breast cancers. 
ER testing by immunohistochemistry is also essential in the proper delivery of tailored 
anti-oestrogen therapy and should be measured by a standard immunohistochemical 
technique using validated methods. Some units may choose not to include PR testing 
(Ref. NICE Guidelines UK and latest EBCTCG data). ER testing is however recommended as 
a mandatory item. Units offering ER testing should participate in quality control of the 
test.  
Her-2 testing by immunohistochemistry or CISH/SISH/ FISH as a primary test should also 
be performed and borderline cases should be verified by repeated or alternate testing 
(ISH for immunohistochemistry and immunohistochemistry for primary FISH). Laboratory-
based quality control is also essential here. 
Level of evidence: II 
4b Definition: The proportion of invasive cancer cases with primary surgery, for which the 
following prognostic/predictive parameters have been recorded: 
• Histological type 
• Grading (according to EU Guidelines) 
• ER & PgR 
• HER 2 
• Pathological stage (T and N) 
• Size in mm for the invasive component 
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• Peritumoral vascular invasion 
• Distance to nearest radial margin 
Minimum standard: >95% 
Target: >98% 
Motivation: Adjuvant therapy and treatment planning. 
Level of evidence: II 
4c Definition: The proportion of non-invasive cancer cases for which the following 
prognostic/predictive parameters have been recorded: 
• Dominant histological pattern 
• Size in mm (best pathology or radiology estimate if 2 stage pathology) 
• Grading (according to EU Guidelines) 
• Distance to nearest radial margin 
Minimum standard: >95%. 
Target: >98%. 
Motivation: Treatment planning. In the framework of BCT, the tumour-free margin should 
ideally be measured in all directions. For BCT in DCIS, margins play probably an even more 
important role (together with age) as a risk factor for LR, compared to invasive cancer. 
Level of evidence: II. 
 
5. Waiting time 
Definition: Time between the date of first diagnostic examination within the breast unit 
and the date of surgery or start of other treatment within 6 weeks 
Minimum standard: >75%. 
Target: >90%. 
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Motivation: to maximize benefit of early detection and to reduce anxiety of the patient 
and her family. 
Level of evidence: IV 
 
6.  MRI availability 
Definition: The proportion of cancer cases examined pre-operatively by MRI. 
Minimum standard: suggested 5%. 
Target: not applicable. 
Motivation: To allow proper diagnostic assessment and to identify size, site and possible 
multifocal and/or controlateral disease. 
Level of evidence: IV 
 
7. Genetic counseling availability (this standard should be collected but is considered 
non-mandatory) 
Definition: The proportion of cancer cases referred for genetic counseling. 
Minimum standard: suggested 5%. 
Target: not applicable. 
Motivation: To allow counseling. 
Level of evidence: IV 
 
8. Multidisciplinary discussion 
Definition: The proportion of cancer patients to be discussed by a multidisciplinary team. 
Minimum standard: 90%. 
Target: 99%. 
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Motivation: To select optimal treatment based on guidelines + clinical criteria; to select 
patients for non-standard treatment based on individual patient needs and tumour-
related factors (e.g. old patients with low-risk BC); to document proposed treatment 
(medico-legal issues); to select patients for clinical trials. Pre-operative discussion seems 
preferable but not obligatory. The consensus is that there should be multidisciplinary 
discussion without specifying the time point. 
Level of evidence: IV (with consensus opinion) 
 
9. Appropriate surgical approach 
9a Definition: The proportion of patients (invasive cancer only) who received a single 
(breast) operation for the primary tumour (excluding reconstruction). 
Minimum standard: 80%. 
Target: 90%. 
Motivation: this also encompasses optimal pre-operative imaging; optimal pre-operative 
handling and optimal pathological examination, all concordant with guidelines. 
Level of evidence: III consensus based on compromise with regard to the discussion in the 
literature on the importance of margins; e.g. Dutch guidelines require no re-excision in 
case of focally involved margins whilst German guidelines require -excision. 
9b Definition: The proportion of patients (DCIS only) who received just one operation. 
Minimum standard: 70%. 
Target: 90%. 
Motivation: this also encompasses optimal pre-operative imaging; optimal preoperative 
handling and optimal pathological examination. 
Level of evidence: II 
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9c Definition: The proportion of patients with invasive cancer and a clinically negative 
axilla (+US ± FNA/CNB) who had sentinel lymph node biopsy. 
Minimum standard: 90%. 
Target: 95%. 
Motivation: LN status is important for prognosis and treatment planning and sentinel 
node biopsy is an accepted means of surgical and pathological staging of the axilla in 
patients with no clinical (including ultrasound and/or cytological) evidence of lymph node 
involvement. 
Level of evidence: II 
9d Definition: The proportion of patients with invasive cancer and axillary clearance 
performed, who had at least 10 lymph nodes examined. 
Minimum standard: 95% 
Target: 98%. 
Motivation: if 10 nodes from level 1 are negative, there is a 90% probability of no 
involvement at any level. A high average lymph node yield reflects both good surgery and 
pathological examination. 
Level of evidence: III 
 
10. Post-operative RT 
10a Definition: The proportion of patients with invasive breast cancer (M0) who received 
post-operative radiotherapy after surgical resection of the primary tumour and 
appropriate axillary staging/surgery in the framework of BCT. 
Minimum standard: 90%. 
Target: 95%. 
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Motivation: Post-operative radiotherapy decreases the local recurrence risk and increases 
long-term survival. Depending on patient- and tumor-related prognostic factors, the 
absolute gain varies so that for selected patients (short life-expectancy based on poor 
WHO ± age and low-risk BC), follow-up alone might be selected. DCIS is kept out because 
of the ongoing controversy and the variance in the guidelines. 
Level of evidence: I 
10b Definition: The proportion of patients with involvement of axillary lymph nodes (P 
pN2a) who received post-mastectomy radiotherapy. 
Minimum standard: 90%. 
Target: 95%. 
Motivation: P pN2a is a general accepted criterion; the debate is ongoing for pN1a 
patients. 
Level of evidence: I (EBCTCG meta-analysis fromPpN1a on). 
 
11. Avoidance of overtreatment 
11a Definition: Proportion of patients with invasive breast cancer not greater than 3 cm 
(total size, including DCIS component) who underwent BCT. 
Minimum standard: 70%. 
Target: 80%. 
Motivation: to conserve the organ with related effects; fewer operations such as delayed 
reconstruction; the rate is difficult to fix firmly; however, as it is related to a large number 
of factors including (expected) cosmetic outcome, patient preference and access to 
radiotherapy. 
Level of evidence: level I evidence of the equivalence of MRM and BCT for early BC. 
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11b Definition: The proportion of patients with non-invasive breast cancer not greater 
than 2 cm who underwent BCT 
Minimum standard: 70%. 
Target: 80%. 
Motivation: To conserve the organ with related effects; fewer operations such as delayed 
reconstruction; the rate is difficult to fix firmly; however, as it is related to a large number 
of factors including (expected) cosmetic outcome, patient preference and access to 
radiotherapy. 
Level of evidence: level II* evidence of the equivalence in terms of overall survival but a 
higher local recurrence rate after BCT as compared to MRM. 
*Randomized trials comparing BCT with mastectomy in patients with DCIS do not exist. 
We have however numerous prospective trials evaluating the role of BCT. Therefore: 
Level II of evidence. 
11c Definition: The proportion of patients with DCIS who do not undergo axillary 
clearance. 
Minimum standard: 95%. 
Target: 98%. 
Motivation: the rate of axillary involvement is about 1–2% and depends on grade and 
diameter (related to occult invasive cancer); axillary surgery increases morbidity. 
Level of evidence: IV, no randomized trials but consensus in all guidelines based on a lot 
of clinical data. 
11d Definition: The proportion of invasive breast cancer patients with pN0 who do not 
undergo axillary clearance. 
Minimum standard: 80%. 
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Target: 90%. 
Motivation: morbidity is dependent on the extent of surgery (SNB < AC). The number of 
contraindications to performing SNB is continuously decreasing. 
Level of evidence: II. A lot of evidence supports the use of SNB for all patients in the 
framework of their primary treatment for BC, unless LN involvement was confirmed 
preoperatively. 
 
12.  Appropriate hormonotherapy 
12a Definition: The proportion of patients with endocrine sensitive invasive carcinoma 
who received hormonotherapy, out of the total number of patients with this diagnosis. 
Minimum standard: 80%. 
Target: >90%. 
Motivation: Endocrine therapy should be offered to patients with endocrine sensitive 
invasive breast cancer. In the last St. Gallen consensus paper, it is pointed out that ER– 
PgR+ tumors are probably artefactual. Despite this thereis no clear evidence that ER– 
/PgR+ patients do not benefit from adjuvant endocrine therapy. 
Level of evidence: I Data from the EBCTCG show that 5 years of tamoxifen in women with 
ER-positive early breast cancer results in an 11.8% and 9.2% absolute benefit in terms of 
15-years relapse-free survival (RFS) and overall survival (OS), respectively. In 
premenopausal women with ER-positive early breast cancer ovarian suppression/ablation 
results in a 4.3% and 3.2% absolute benefit in terms of 15-years RFS and OS, respectively. 
Data from more recent trials show that the introduction of anaromataze inhibitor in 
postmenopausal patients with ER-positive early breast cancer further reduce the risk of 
tumor relapse over single agent tamoxifen without improving survival. 
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12b Definition: The proportion of patients with ER– and PgR– carcinoma who did not 
receive adjuvant hormonotherapy, out of the total number of patients with the same 
diagnosis. 
Minimum standard: 98%. 
Target: 100%. 
Motivation: Endocrine therapy should not be offered to patients with ER- and PgR-
negative invasive breast cancer. 
Level of evidence: I. Data from the EBCTCG show no benefit from endocrine therapy in 
patients with ER-poor breast cancer. 
13. Appropriate chemotherapy and other medical therapy  
13a Definition: The proportion of patients with ER– (T > 1 cm or Node+) invasive 
carcinoma who received adjuvant chemotherapy, out of the total number of patients with 
the same diagnosis. 
Minimum standard: 80%. 
Target: >90%. 
Motivation: Chemotherapy should be offered to patients with ER-negative invasive breast 
cancer (T > 1 cm or Node +). 
Level of evidence: I. Data from the EBCTCG and from several clinical trials offer evidence 
of benefit from chemotherapy versus no treatment in terms of RFS and OS in patients 
with ER-negative tumors. 
13b Definition: The proportion of patients with N+ or N– T > 1 cm HER2+ (IHC 3+ or in situ 
hybridization positive FISH +) invasive carcinoma treated with chemotherapy and who 
had adjuvant trastuzumab, out of the total number of patients with the same diagnosis. 
Minimum standard: 80%. 
 Management of a High Quality Comprehensive Breast Center 
75 
 
Target: >90%. 
It is recommended to follow the ASCO guidelines for HER2testing. 
Motivation: Trastuzumab should be offered to patients with HER2-positive (IHC 3+ or 
FISH+) invasive breast cancer N+ or N– T > 1 cm if they receive adjuvant chemotherapy. 
Level of evidence: I. Clinical trials have shown that adjuvant trastuzumab improves RFS 
and OS in patients with node positive or node-negative T > 1 cm HER2+ early breast 
cancer above chemotherapy alone. 
13c Definition: The proportion of patients with HER2 negative invasive carcinoma who did 
not have adjuvant trastuzumab, out of the total number of patients with the same 
diagnosis. 
Minimum standard: 98%. 
Target: 100%. 
Motivation: Trastuzumab should not be offered to patients with HER2 negative invasive 
breast cancer. 
Level of evidence: II. A Study conducted in the metastatic setting showed no advantage 
from a trastuzumab based treatment in patients with HER2negative breast cancer. 
13d Definition: The proportion of patients with HER2+ invasive carcinoma who had 
adjuvant chemotherapy, out of the total number of patients with the same diagnosis who 
had adjuvant trastuzumab. 
Minimum standard: 95%. 
Target: 100%. 
Motivation: Chemotherapy should be offered to patients with HER2 positive (IHC 3+ or 
FISH+) invasive breast cancer who are candidates to receive trastuzumab. 
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Level of evidence: IV – All the studies investigating the role of trastuzumab in the 
adjuvant setting incorporated chemotherapy in the treatment plan (sequential or 
concomitant strategy). No data are available on the role of single agent trastuzumab (or 
in combination with only an endocrine treatment) in the adjuvant setting. 
13e Definition: The proportion of patients with inflammatory breast cancer (IBC) or locally 
advanced non-resectable ER carcinoma who had neo-adjuvant chemotherapy over the 
total of patients with the same diagnosis. 
Minimum standard: 90%. 
Target: >95%. 
Motivation: IBC requires sequential multidisciplinary treatment with primary or neo-
adjuvant chemotherapy representing the mainstay of treatment. Tumor downstaging is 
mandatory to reconvert initially non-resectable locally advanced breast cancer to a 
resectable stage. 
Level of evidence: II several trials have shown that chemotherapy allows tumor shrinkage 
in patients with inflammatory BC and locally advanced non-resectable breast cancer. 
 
14.  Appropriate staging procedure 
14a Definition: The proportion of women with stage I breast cancer who do not undergo 
baseline staging tests (US of liver, chest X-ray and bone scan). 
Minimum standard: 95%. 
Target: 99%. 
Motivation: As demonstrated by clinical studies and indicated in the various society’s 
recommendations the percentage of patients with asymptomatic metastases detected 
with these tests is irrelevant to the management of stage I breast cancer. 
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Level of evidence: III. 
14b Definition: The proportion of women with stage III breast cancer who undergo 
baseline staging tests (US of liver, chest X-ray and bone scan). 
Minimum standard: 95%. 
Target: 99%. 
Motivation: CT scan, bone radiographs, MRI-, PET-scan should be used only when 
indicated by symptoms, in the framework of clinical trials and/or to clarify an abnormal 
outcome of the mandatory diagnostic procedures. 
Level of evidence: III. 
15. Perform appropriate follow-up 
Definition: The proportion of asymptomatic patients who undergo routine annual 
mammographic screening and clinical evaluation every 6 months in the first 5 years after 
the operation. 
Minimum standard: 95%. 
Target: 99%. 
Motivation: At least three sets of evidence based guidelines recommend periodic history 
taking, physical examination and yearly mammography. No consensus exists on the 
frequency and duration of physical examination. 
Level of evidence: I. 
16. Avoid inappropriately intensive follow-up 
Definition: The proportion of asymptomatic patients who do not undergo a follow-up 
protocol more intensive than local examination (mammography, US and clinical 
evaluation every 6/12 months in the first 5 years after the operation). 
Minimum standard: 95%. 
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Target: 99%. 
Motivation: two randomized trials showed no survival benefit from intensive screening 
for asymptomatic metastatic disease. 
Level of evidence: I. 
17.  Availability of nurse counseling 
17a Definition: The proportion of patient referred for nurse counseling at the time of 
primary treatment. 
Minimum standard: 85%. 
Target: 95%. 
Motivation: Oncology nurses can give assessment and psychological support to women 
undergoing breast cancer treatment. Adequate information can help women in finding 
more balance and sense of control with respect to the disease. 
Level of evidence: IV. 
17b Definition: All women with a diagnosis of breast cancer should have direct access to a 
breast care nurse specialist for information and support with treatment-related 
symptoms and toxicity during the treatment and follow-up and rehabilitation after initial 
treatment. 
Motivation: All these symptoms should be recognized and related if indicated. 
Minimum standard: 95%. 
Target: 99%. 
Level of evidence: evidence-based recommendations of the major scientific societies. 
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11. Policlinic work and screening 
The screening for breast cancer is the key point in the lowering the mortality and in 
succeeding of the treatment. 
Calling women over 40 years old to perform a mammography and performing to them a 
routine physical examination leads to early diagnosis of breast cancer or breast disease 
that need periodic control and helps to inform and educate women how they should 
autopalpate their breast and ask for an expert opinion any time they have any doubt or 
occur to palpate a nodule. 
Explaining to patients the importance of the screening and of a well performed physical 
examination helps to create a confidential relationship doctor-patient. The screening in 
women older than 40 years old is mandatory and a recall each two years in cases of clear 
mammogram is required. Screening and policlinic physical examination does not only help 
in early diagnosis but also in creating a data base and for all the patients that will help in 
the follow-up work. 
Explaining to them how the mammography is performed and its importance in prevention 
of radical interventions in case of breast cancer and its role in early diagnosis will help in a 
better collaboration and will assure the presence in the later recalls. 
Forming a data base including family history (anamnesis) physiologic history( menarca, 
regularity of menstrual cycle, any pregnancy, any abortion, breast feeding, months of 
breast feeding, hrt, contraceptive treatment), pathologic history ( any previously 
diagnosed breast disease or cancer, any ovary or uterus disease, any endocrinal disease ), 
habits ( smoking, coffee, tea, Coca-Cola, alcohol, drugs) pharmacological history  etc. 
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According to the outcome of the mammogram an ultrasound may also be required to be 
performed, this depends on the breast architecture on the age and whether there is any 
doubt to be cleared from the outcome of the mammogram. 
So it is important for a breast center to offer the complete radiologic diagnosis, there 
must be in the same structure of the policlinic care at least a mammography room, an 
ultrasound device and the most important a specialized radiologist in breast cancer. 
The risk of breast cancer is age-dependent. The probability of developing breast cancer is 
equal to 0.04% per year for average risk women between age 30 and 39 and increases to 
>10% per year in those over 80 years. 
Breast cancer in women under 40 years is not a common condition. However, a dramatic 
increase in the number of breast cancers diagnosed in premenopausal women has been 
reported in several countries. 
In the United States, 5.5% of breast cancers occur in women younger than the age of 40 
years. 
 Approximately one in forty women diagnosed with early breast cancer is very young (<35 
years). Breast cancer in young women is associated with a positive family history and 
gene mutations more frequently than in older women.  
 In addition, working groups also decided to focus on recommendations specific for this 
age group. Yet, we still want to emphasize those general recommendations that do not 
necessarily differ with age but are particularly important for young women. We, thus, 
want to avoid over- and under-treatment based more on physicians’ concern than on 
actual evidence. During the review of all available evidence, is realized that there are 
many issues regarding the management of young women for which evidence is lacking. 
Such issues are, therefore, highlighted as research priorities. 
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Issues of body image, sexuality, fertility and lactation must be discussed with young 
women with breast cancer. These issues are of course important for women of all ages 
albeit the actual importance is weighted on an individual basis that is not necessarily 
related to age. 
Issues of fertility and lactation are, by definition, related to age and menopausal status 
even outside breast cancer. In particular, fertility issues must be discussed before the 
start of any type of anticancer treatment, since treatment consequences may be 
irreversible and there is a predefined time schedule specific to each fertility preservation 
intervention that may also impact on anticancer therapy. All these issues must continue 
to be discussed throughout follow-up. Age has been shown in several studies to be an 
independent adverse prognostic factor for women with a diagnosis of breast cancer. 
There is a continuous linear effect, with a 4% decrease in distant recurrence and 6% in 
local recurrence for every additional year of age. 
There are also data showing a higher risk of contralateral BC in young women, in 
particular in BRCA mutation carriers and increased mortality in young women. 
While some preliminary studies suggest that the distribution of the different biological 
subtypes of breast cancer is different in young women with a higher prevalence of triple 
negative and Human Epidermal Growth Factor Receptor 2 HER-2+ disease a clear 
molecular characterization of breast cancer in these patients is lacking and is a RESEARCH 
PRIORITY. In addition, it should be recognized that there are some rare histological 
subtypes such as “juvenile secretory adenocarcinoma” that are more frequent in the very 
young women. Despite the fact that they are triple negative their prognosis is good. 
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Screening 
 
Screening is predominantly a radiological procedure with particular emphasis placed on the 
optimal balance of sensitivity and specificity. Many abnormalities are impalpable and priority 
is given to maximizing the cancer detection rate while minimizing anxiety and reducing the 
benign biopsy rate by paying sufficient attention to the accuracy of non-operative diagnostic 
techniques. The radiologist has the role of prime responsibility in screening. 
 
Women at average risk 
 
At the present time, mammography is the diagnostic modality of choice for screening for 
early breast cancer.
22
 
23
 The sensitivity of mammography in women over the age of 50 has 
been estimated to be around 85% (range 68% to >90%) while it was reported to be lower 
(range 62–76%) in women between 40 and 49 years.
24
 The advent of full-field digital 
mammography suggests a further positive clinical impact on early detection of breast 
cancer.
25
 Studies comparing the diagnostic performance of full-field digital 
mammography with screen-film mammography in a corporate screening, showed a 
significantly higher cancer detection rate and positive predictive value for full-field digital 
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 Hackshaw AK, Paul EA. Breast self-examination and death from breast cancer: a metaanalysis. Br J Cancer 
2003;88:1047–53. 
23
 . Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. 
J Natl Cancer Inst 2002;94(19):1445–57. 
24
 Breast Screening Programme. England 2007–2008. Published January 28, 2009. Office of National 
Statistics, London. 
25
 Vinnicombe S, Pinto Pereira SM, McCormack VA, Shiel S, Perry N, Dos Santos Silva IM. Full-field digital 
versus screen-film mammography: comparison within the UK breast screening program and systematic 
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mammography, especially in women under the age of 50.
26
Results from randomized 
clinical trials (RCTs) showed that screening mammography reduces the number of deaths 
from breast cancer in women between 40 and 74 years of age.
27
  
28
A recent systematic 
analysis of major RCTs showed that screening mammography provides an average 
mortality reduction of about 19% with its major impact (mortality reduction of 30%) in 
the age group of 49–59 years. 
29
 Screening program must consider the incidence of the 
disease, the performance of the diagnostic tests as well as the costs to both patients and 
society. The low incidence of sporadic breast cancer before the age of 40 and the 
suboptimal performance of diagnostic modalities in these women justify the absence of 
trials investigating not only the efficacy but also the feasibility of breast cancer screening 
program in women under 40 years of age. In addition, studies conducted in women under 
the age of 40 years not only failed to show a benefit from regular screening 
mammography but also demonstrated high recall rates, high rates of additional imaging 
and low cancer detection rates.
30
 The efficacy of a baseline mammogram for women at 
average risk at the age of 35– 40 years to provide a comparison image available when 
regular screening begins at the age of 40 years or older,  was tested in the past, yet there 
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was no sign of benefit from such a baseline screening.
31
 Breast augmentation is 
increasingly performed in young women for cosmetic purposes. The presence of breast 
implants does not represent a risk factor. Several case control and cohort studies have 
not shown an increased risk for breast cancer due to augmentation mammoplasty.
32
 To 
date no studies have investigated screening programs or imaging surveillance in 
aesthetically augmented women less than 40 years who are at average risk. There are 
some data suggesting that the presence of implants may lead to a loss of 28–49% of the 
breast on mammographic view.
33
 The sensitivity of a screening mammography in 
asymptomatic women is lower in women with breast augmentation in comparison to 
those without (45.0% versus 66.8%); yet, the specificity is slightly higher in women with 
augmentation (97.7% versus 96.7%).
34
 It was reported that – at time of diagnosis – breast 
cancers are more frequently palpable in augmented women than in those without 
implants (75% versus 54%).
35
 This observation raises the hypothesis that the presence of 
breast implants may lead to a delayed diagnosis with all its consequences. Young women 
planning to have a breast augmentation surgery should be specifically informed about 
this issue. However, published studies confirmed that prognosis, disease-free time and 
survival rates are similar between augmented and non-augmented women with breast 
cancer. 
36
 No evidence exists for recommending periodic contrast-enhanced MRI in 
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women at average risk, both with or without cosmetic breast implants.
37
The available 
evidence of the benefit of breast self examination (BSE) is limited and mostly relates to 
increased breast health awareness. 
 
In summary 
 
 Regular breast self-examination and clinical breast examination should be recommended 
for all the women at average risk under 40 years of age. Women also need to be informed 
about the limitations and risks of breast examination. The ideal time for breast 
examination is after menstruation (level of evidence (LoE) expert opinion). 
The panel emphasizes that any new breast abnormality in young women should be 
thoroughly investigated (imaging, needle biopsy), even though the incidence of breast 
cancer is lower in this age group, to avoid misdiagnosis and delayed diagnosis, and 
importantly to minimize unnecessary surgical intervention for non-malignant conditions. 
Adequate information about genetic counseling and imaging surveillance programs 
should be provided to all young women with a strong family history of breast cancer (LoE 
expert opinion). 
There is no evidence to recommend regular diagnostic surveillance in augmented and 
non-augmented women at average risk under 40 years of age (LoE III). 
A pre-operative diagnostic check, including clinical examination, mammography (if the 
women are between age 35 and 40 years) and/or ultrasound is suggested in women at 
average risk under the age of 40 years, undergoing aesthetically breast augmentation 
(LoE expert opinion). 
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Women with a family history suggesting an inherited predisposition to breast cancer 
should have their risk assessed by an appropriately trained professional group (e.g. 
genetic counseling) (LoE expert opinion). If found to be at high risk (20–30% lifetime risk 
or greater), these women should be given oral and written information regarding their 
risk and the risks and benefits of mammography and MRI screening or alternative risk-
reducing interventions; if these women accept to be screened by MRI, they should be 
informed about screening intervals and logistics (LoE expert opinion). Lifetime risk 
thresholds for including women in surveillance programs with annual MRI may be 
determined on the basis of regional or national considerations reflecting an area-specific 
cumulative risk in the general population, resource availability and practical feasibility 
(LoE expert opinion). 
High-risk breast screening utilizing MRI should be conducted only by a 
nationally/regionally approved and audited service or as part of an ethically approved 
research study. Periodical audits should be undertaken to ensure that high sensitivity is 
achieved and that the early recall rate (MR imaging more frequent than annually) is less 
than 10%, and to monitor detection rate, needle biopsy rate and interval cancers (LoE 
expert opinion). 
 Annual MRI screening should be available starting at age 30. Starting annual screening 
before age 30 may be discussed, such as in BRCA1 or BRCA2 mutation carriers (starting 
between age 25 and 29 years) and TP53 mutation carriers (starting at age 20) (LoE IIb). 
 Annual MRI screening should be offered to: 
• BRCA1, BRCA2 and TP53 mutation carriers’. 
• Women at 50% risk to be carriers of BRCA1, BRCA2 or TP53 mutation (first-degree 
relatives of mutation carriers) (LoE-Ib). 
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• Women from families not tested or inconclusively tested for BRCA mutation with a 20–
30% lifetime risk or greater (LoE-II). 
• Women with prior mantle radiotherapy before age 30 (e.g. for Hodgkin disease), starting 
8 years after their treatment (LoE III). 
• Women at high risk and who were already diagnosed and treated for breast cancer 
should be included in screening programs including MRI (LoE-IIb). 
• Women of any age undergoing prophylactic mastectomy should have a MRI examination 
within the 3 months before surgery to screen for occult breast cancer (LoE expert 
opinion). 
Screening mammography should not be performed in high-risk women below 35 years as 
there is no evidence that the benefits outweigh the risks in this young age group (LoE 
expert opinion). 
In TP53 mutation carriers of any age, annual mammography can be avoided based on the 
discussion of risks and benefits from radiation exposure (LoE expert opinion). 
 Annual mammography may be considered for high risk women starting at age 35 years 
(LoE III). 
If annual MRI is performed, additional screening with breast ultrasound (US) and clinical 
breast examination (CBE) are not necessary as there is no evidence of any benefit added 
to MRI (LoE II). They are however recommended in women under 35 years who do not 
tolerate or have contraindications to MRI or gadolinium-based contrast administration 
(LoE expert opinion). 
Cases requiring workup after MRI should be initially assessed with conventional imaging – 
re-evaluation of mammography and targeted US (LoE II). In cases of suspicious findings 
solely detected by MRI, MR guided biopsy localization should be performed (LoE I). 
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Risk factors such as prior diagnosis of invasive breast cancer or Ductal Carcinoma In Situ 
(DCIS), atypical ductal hyperplasia, lobular intraepithelial neoplasia, heterogeneous or 
dense breasts on mammography, if not associated with other risk factors, do not confer 
an increased risk justifying the use of screening MRI (LoE III). 
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12. Clinical pathway after established diagnosis 
 
Modern diagnosis of breast disease is a multidisciplinary activity requiring trained and 
experienced professionals using specialized equipment with up to date sampling and 
other diagnostic techniques. Triple assessment, i.e. clinical examination, imaging, and 
cytological / histological sampling is still regarded as the gold standard. As far as possible 
we have tried to avoid screening or treatment issues unless of particular relevance to 
diagnostic activity. 
In symptomatic activity the clinician has the role of prime responsibility. Usually, this 
person is either the referring General Practitioner, or the surgeon or radiologist that the 
patient is referred on to for further investigations. The clinician may also be regarded as 
any medical professional who is trained and skilled specifically in clinical examination of 
the breast. In these circumstances however the role of imaging, interpretation and 
cytological/histological sampling procedures will still be paramount as supportive 
diagnostic activities.  
Practices are likely to vary across Member States according to healthcare environments 
and the availability of trained personnel, however these variations must not be allowed to 
interfere with the achievement of set targets and outcome measures. Any variation to 
standard procedures in the diagnostic work-up should be tolerated only if documented 
audit demonstrates satisfactory outcomes and provision of care.  
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It is strongly recommended that all women with breast symptoms should be referred to a 
specialist breast unit, the requirements for which have already been laid out by 
EUSOMA
38
. However it is important to recognize that in a decentralized healthcare setting 
many women will not undergo more than basic imaging following a General Practitioner 
referral, and the benefits of full multidisciplinary assessment will not be available to 
them, or indeed necessary for many of them. These chapters will therefore attempt to 
cover all pertinent aspects of basic diagnosis as well as assessment and underline the 
importance of ensuring that women who do require further assessment are not denied it. 
In order to ensure this, agreed protocols should be set up between basic breast imaging 
units and specialist breast assessment units. Throughout this text the terms patients and 
women are referred to at various points as appropriate. It is recognized that on occasions, 
male patients will also require the services of a diagnostic breast clinic.  
 
Asymptomatic women do not necessarily require initial clinical examination or other 
imaging investigation apart from mammography if taking part in a breast screening 
program. However it is regarded as good practice that all women with breast symptoms 
undergo a clinical examination prior to any further investigation requested, and that this 
be performed by a suitably trained and experienced clinician. 
The diagnosis of breast cancer in young women may be difficult because of dense breast 
tissue, lack of previous routine breast screening and shorter tumor doubling times. For 
this age group, due to these intrinsic difficulties in diagnosis, imaging evaluation of breast 
lesions should only be done by experienced professionals. Breast cancer in young women 
more frequently presents with a higher disease stage and poorer prognosis than in older 
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women. In fact, >90% of young women with breast cancer are symptomatic, but it is 
important to consider that most of the young women presenting with breast symptoms 
do not have breast cancer. 
 
Only a few studies in the literature have investigated the diagnostic performance of 
imaging in young women with breast symptoms. The cancer detection rate of 
mammography in symptomatic women under 40 years ranges in the literature between 
55% and 86%.2 In a retrospective study investigating 239 cases of breast cancer in women 
less than 40 years during a period of 10 years, Foxcroft and colleagues reported that 
70.8% of the subjects had a mammographic abnormality which was correctly classified as 
malignant in 52.8%. Mammography was the only satisfactory imaging modality for 
demonstrating small clusters of microcalcifications. 
39
 Houssami and colleagues 
retrospectively evaluated the diagnostic performance of conventional imaging in 240 
patients with breast cancer of whom 64 were under 40 years. In this subgroup, the 
sensitivity of mammography ranged between 69% and 76% while the specificity was 
between 83% and 96%. 
40
 Since ultrasound is less affected by breast density, it shows a 
better diagnostic performance than mammography in symptomatic young patients. In the 
series of Foxcroft, it showed an abnormality in 95.5%, which was correctly classified as 
benign or probably benign in 25.5% of the cases. In the study of Houssami, the breast 
cancer detection rate of ultrasound was 84% with specificity between 84% and 91%. 
These results, associated with the potential damage from ionizing radiation exposure, 
suggest that ultrasonography could be the primary imaging test in symptomatic women 
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younger than 40 years (LoE Expert Opinion). As in older women, ultrasound guided biopsy 
should be performed if a sonographically suspicious finding is detected. Since malignant 
lesions may mimic benign lesions in high-risk women, ultrasound guided biopsy should 
also be considered when a probably benign sonographic finding is detected in these 
patients. The subsequent use of mammography should be decided on the basis of the 
biopsy result. If the result is positive or inconclusive, mammography is indicated to define 
the extent of the disease or to add further diagnostic information, respectively. If 
ultrasound is negative, the potential benefit of a clinical biopsy and/or mammography is 
related to the degree of clinical suspicion and the breast cancer prevalence. As in older 
women, accurate pre-surgical local staging of breast cancer is required to ensure a 
complete excision of the disease. In the study of Foxcroft, mammography was unreliable 
for diagnosing multifocality while ultrasound was useful in the detection of other disease 
foci. In addition, ultrasound was also more reliable in the assessment of the size of the 
lesion as confirmed by pathology. These findings suggest that bilateral breast ultrasound, 
including the axilla, should be performed in the diagnostic workup of all breast cancer 
patients less than 40 years. The role of MRI in the preoperative setting is still 
controversial. MRI is recognized as the most sensitive modality both in identification and 
local staging of breast cancer 
41
 but shows limitations in terms of variable specificity 
42
 
MRI shows a better diagnostic performance in staging invasive lobular breast cancer 
43
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and in identifying contralateral disease foci. 
44
 It has been shown that MRI is more 
sensitive than conventional imaging in the evaluation of an extensive intraductal 
component (EIC) and DCIS without microcalcifications, both of which are more frequent 
in young and in high-risk women. MRI also has a higher negative predictive value (97% for 
a lesion of P2 cm) for measuring the distance between nipple/areolar complex and the 
lesion itself, 
45
 which is useful for planning nipple sparing mastectomy. On the other hand, 
the main concerns regarding MRI are its unclear impact on clinical outcome and the 
potential risk of surgical overtreatment. Two randomized prospective trials evaluated the 
impact of preoperative MRI on surgical outcome.
46
 In both trials, the introduction of MRI 
in the management of patients undergoing surgery did not lead to a reduction of re-
excision rate. Moreover, in the COMICE trial the mastectomy rate was significantly higher 
in the arm with MRI with respect to that without (7% versus 1%). Only retrospective 
studies investigated the impact of MRI on long-term clinical outcomes. In the study of 
Fischer et al. 
47
 the IBTR rate at a follow-up of 40 months was 1.2% for the 86 patients 
who underwent pre-operative MRI with respect to 6.8% for the 133 without pre-
operative MRI. Conversely, the studies of Solin et al.
48
 and Hwang et al. 
49
 reported no 
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differences in IBTR rate between patients with and without preoperative MRI. In brief, 
even though MRI is the most sensitive modality in the identification of breast cancer, at 
present there is no evidence that detection of additional malignant foci with MRI before 
treatments translates into patient benefit from both surgical care and prognosis. 
50
 
51
 
However, it should be taken into account that published evidence does not reflect breast 
cancer patients under 40 years. 
52
 
53
 
 
 
 In summary 
As in older women, young women presenting with breast symptoms and a strong 
suspicion of breast cancer should be evaluated by triple assessment (clinical examination, 
imaging and cytological/histological examination) in order to exclude or confirm a 
diagnosis of cancer (LoE IIa) When a palpable abnormality is present, patients should have 
ultrasound followed, if required (in case of Breast Imaging-Reporting And Data System 
(BIRADS) 3–5), by core biopsy and/or fine needle aspirate cytology (LoE IIa). The 
subsequent use of mammography should be based on the biopsy result (LoE expert 
opinion). If the result is positive or inconclusive, mammography is indicated to define the 
extent of disease or to add further diagnostic information (LoE expert opinion). 
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If the ultrasound is negative (BIRADS 1–2), the benefit of a clinical biopsy and/or 
mammography is related to the degree of clinical suspicion and the breast cancer 
prevalence (LoE expert opinion). 
As in older women, a lesion considered malignant following clinical examination, imaging 
or cytology alone should, where possible, have a histopathological confirmation of 
malignancy before any surgical procedure takes place. Immunohistochemical biomarkers 
(oestrogen and progesterone receptors status, HER- 2 status and proliferation (e.g. Ki67)) 
should be measured on all invasive primary breast cancers, ideally in both core biopsy and 
surgical specimen. 
 As in older women, in cases of possible or scheduled primary chemotherapy, 
immunohistochemical biomarkers (oestrogen receptor (ER), partial response (PR), HER-2 
and proliferation) should be measured in the core biopsy before the beginning of medical 
treatment. 
 If malignancy is diagnosed, bilateral ultrasound of the breast and axilla should be 
performed for local staging of the disease (LoE IIa). 
There is no evidence to recommend routine preoperative MRI in young women with 
breast cancer. Indications for MRI are the same as for older women, including patients 
with newly diagnosed invasive lobular cancer (LoE IIa), patients at high-risk for breast 
cancer (LoE IIb), patients with a size discrepancy of more than 1 cm between 
mammography and ultrasound and an expected impact on the treatment decision (LoE 
IIb). Because of the special characteristics of young patients, multidisciplinary evaluation 
of the advantages and disadvantages of pre-operative MRI taking into account the 
planned surgical approach is recommended (LoE expert opinion).  Additional lesions 
identified by MR that may modify the already planned surgical treatment should be 
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initially assessed with conventional imaging (re-evaluation of mammography and 
targeted US) and verified by imaging-guided biopsy (LoE II). In cases of suspicious findings 
solely detected by MRI, MR-guided biopsy localization should be performed (LoE I). 
 
Management of pre-invasive disease  
 
Chemoprevention 
Chemoprevention treatments should preferably be administered within study protocols. 
Pre-invasive lesions (DCIS–DIN) Ductal Intraepithelial Neoplasia 
Counseling 
Counseling in young women at increased risk for invasive recurrence or breast cancer 
should include family planning issues (fertility and contraception), even at diagnosis of a 
pre-invasive lesion. 
Surgery 
The panel agrees that the surgical treatment of young patients presenting with 
intraductal neoplasia should in general not differ from that in older patients. 
Nevertheless, young age is a variable that independently increases the local recurrence 
rate. 
54
 Therefore, the lesion must be removed with adequate surgical margins of at least 
2 mm. Achievement of clear margins (at least 2 mm) are strongly recommended. For 
those women who do not want to undergo re-excision or mastectomy in cases of close 
proximity to or focal positivity of margins, information needs to be given concerning the 
increased risk of local recurrence. As there is lack of data regarding safety of skin-sparing 
mastectomy in young patients, careful preoperative evaluation must be performed in 
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order to properly select patients suitable for skin-sparing mastectomy, especially with 
nipple-areola complex (NAC) preservation. In such patients, evaluation of the retro-
areolar margin, both intra-operatively by frozen section and post-operatively, is 
recommended. There is NO evidence for the necessity to perform prophylactic 
contralateral surgery in young women with unilateral DCIS or LIN (lobular in situ 
neoplasia) unless they are BRCA positive. As in older patients, sentinel lymph node biopsy 
(SLNB) is not routinely indicated in young patients with intraductal neoplasia. 
Nevertheless, it should be considered whenever there is a substantial risk of 
underestimating the real disease extent by the pre-operative diagnosis (for example, a 
large cluster of microcalcifications or extensive multifocal lesions) in order to avoid the 
risk of a second operation in the event that invasive disease is diagnosed at the final 
histology. The panel agrees that SLNB is strongly recommended in all patients undergoing 
mastectomy. 
 
Radiotherapy 
 
The radiotherapy trial evidence is supported by retrospective subgroup analyses 
according to age in large prospective trials. There is NO role for post-mastectomy 
radiation therapy in cases of DCIS with clear margins. However, it should be noted that 
older evidence refers to mastectomy that almost invariably included excision of the NAC. 
There is NO current evidence regarding preservation of the NAC, particularly not for 
young women with their known high-risk of recurrence. For this reason, data are urgently 
needed and this topic thus constitutes a RESEARCH PRIORITY. The current lack of 
evidence means that the issue of postmastectomy radiotherapy after preservation of the 
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NAC requires a full discussion and decision by the multidisciplinary team with 
psychosocial issues considered. After breast conserving surgery, whole breast 
radiotherapy (WBR) should be given (LoE I). An additional radiation dose to the tumour 
bed (boost) should be considered or entry into an appropriate prospective clinical boost 
trial 
55
 (LoE II). There is NO evidence to support withholding radiotherapy after breast 
conserving therapy for DCIS in young women. It should be noted, however, that all 
studies addressing this point predominantly looked at older women. Partial breast 
irradiation (PBI), such as intra-operative radiotherapy (IORT) or other techniques, is not 
recommended as there are no data for DCIS. All randomized data on PBI so far refer to 
invasive cancers. 
 
Early breast cancer 
 
All patients with breast cancer should be discussed within the multidisciplinary team 
before any treatment decision making. In patients with unifocal operable tumors too 
large for breast conserving surgery, down staging with neoadjuvant systemic therapy 
should be considered (LoE IA). Although there has been a suggestion of higher local 
relapse rates after neoadjuvant chemotherapy and breast conservation, especially in 
young women,
56
 there appears to be no long-term significant survival harm from 
neoadjuvant chemotherapy and subsequent conservative surgery in young women. 
57
 The 
NSABP B-24 study demonstrated that women <50 years was the only group benefitting 
                                                           
55
 Omlin A, Amichetti M, Azria D, et al. Boost radiotherapy in young women with ductal carcinoma in situ: a 
multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 2006;7(8):652–6. 
56
 Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with 
operable breast cancer. J Clin Oncol 1998;16(8):2672–85. 
57
 Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a 
meta-analysis. J Natl Cancer Inst 2005;97(3):188–94. 
 Management of a High Quality Comprehensive Breast Center 
101 
 
long term from neoadjuvant compared to adjuvant treatment.
58
 Outside clinical trials, if 
adjuvant chemotherapy and radiotherapy are indicated, chemotherapy should be given 
first in young women, as in other age categories (LoE IA). It is recommended to start 
adjuvant chemotherapy or radiotherapy within 8 weeks of completion of surgery (LoE IC). 
 
(Neo)adjuvant chemotherapy 
 
There is no evidence to recommend a specific chemotherapy regimen for young women. 
Therefore, as for all stage I–III breast cancer patients, the preferred regimens are 
standard anthracycline-based regimens with or without a taxane (LoE IA). A sequential 
regimen of anthracycline-based chemotherapy followed by adequately dosed CMF (oral 
or day 1&8 iv) or a combination of taxane and cyclophosphamide are also valid options in 
some circumstances. However, as mentioned above, young age might be just the 
phenotype for a genetic/biologically different cancer associated with an adverse 
prognosis.
59
 Accordingly, very young women should probably be treated with a standard 
regimen including at least an anthracycline and a taxane. The neoadjuvant Gepartrio trial 
demonstrated that age below 40 was a significant independent predictive factor for 
efficacy of a Taxotere, Adriamycin and Cyclophosphamide (TAC)-based therapy overall, 
and in the subgroup of triple negative breast cancer. 
60
 Some oncologists use dose-dense 
regimens more often in young women, but to date, only patients with hormone receptor-
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negative breast cancer have shown benefit from this approach. 
61
 There are several 
acceptable regimens recommended, for example, those suggested by the German AGO 
Breast Commission. 
62
 Standard duration of treatment (minimum of four and maximum of 
eight cycles) should also be prescribed. Data available suggest at least equal or superior 
efficacy for sequential regimens over combinations (for example of anthracyclines and 
taxanes)
63
 
64
: Young age by itself should not be an indication to prescribe a combination 
of cytotoxic agents. Despite older age being an additional risk factor for febrile 
neutropenia, young women have also a risk of developing (febrile) neutropenia if treated 
with a chemotherapy regimen associated with a risk of febrile neutropenia greater than 
20%, such as TAC or dose-dense regimens. 
65
 According to the updated European 
Organization for Research and Treatment of Cancer (EORTC) guidelines on G-CSF 
(granulocyte colony-stimulating factor) use, primary prophylactic G-CSF is recommended 
if the individual patient’s risk of febrile neutropenia is 20% or higher. Secondary 
prophylaxis with GCSF is recommended for patients who experienced a neutropenic 
complication from a prior cycle of chemotherapy (LoE IA).  Women receiving an adjuvant 
anthracycline–taxane regimen should be closely monitored for febrile neutropenia, 
independently of age. High-dose chemotherapy with stem-cell transplantation cannot be 
recommended for patients with primary or metastatic breast cancer (LoE IA). 
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(Neo)adjuvant endocrine therapy 
 
Neoadjuvant endocrine therapy should not be used in young women outside clinical 
trials. Young patients with hormone receptor positive breast cancer should receive 
adjuvant endocrine treatment with tamoxifen for 5 years (LoE IA), with or without a 
Gonadotropin-releasing hormone (GnRH) analogue. Patients should be informed of the 
possibility of getting pregnant while on tamoxifen, despite developing amenorrhoea, and 
of the need for adequate non-hormonal contraception. If a GnRH analogue is used in this 
age group, it should be given on a monthly basis (and not on a 3-monthly basis) to 
optimise ovarian suppression and efficacy. If the combination of tamoxifen and GnRH 
analogue is given, estradiol levels should be checked on a regular basis (at least every 6 
months) because in some patients ovarian suppression is not achieved. Due to the lack of 
reproducibility, estradiol levels should be measured always in the same laboratory and 
preferably in a central reference laboratory. As a consequence, patients should also be 
informed to undertake effective non-hormonal contraception while on treatment. In 
cases of inadequate suppression alternative strategies should be discussed 
(oophorectomy or continuation of tamoxifen alone). Women should be fully informed 
about the risk of stopping tamoxifen treatment early (the earlier the interruption the 
higher the risk). Young women with stage I or II breast cancer who cannot take tamoxifen 
(due to contraindications or severe side effects) should receive a GnRH analogue (LoE IA). 
The optimal duration of this treatment is currently unknown and is a RESEARCH PRIORITY. 
There are conflicting data (ZORO and PROMISGIM6 studies) regarding the use of GnRH 
analogues to protect ovarian function during chemotherapy and additional studies are 
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ongoing (see also below).
66
 
67
 
68
Aromataze inhibitors alone are contra-indicated in 
premenopausal women. Aromataze inhibitors combined with GnRH analogue should not 
be used in young early breast cancer patients outside clinical trials, before the results of 
the SOFT and TEXT trials are available. Additionally, aromataze inhibitors alone should not 
be used in young patients with chemotherapy-induced amenorrhoea, unless 
postmenopausal status is definitively proven. 
CYP2D6 polymorphism analysis cannot be recommended outside clinical studies. 
Usually, the younger the woman, the worse are the side effects of endocrine therapy; 
therefore supportive measures are needed. Research on age-related quality of life issues 
should be a RESEARCH PRIORITY. 
The optimal duration of endocrine therapy for high risk premenopausal women to 
balance potential benefits and side effects associated with the treatment still needs to be 
determined and is a RESEARCH PRIORITY. 
 
 Adjuvant anti-HER-2 therapy 
 
One year treatment with adjuvant trastuzumab, together or after chemotherapy, is 
indicated for women withHER-2-positive, node-positive or high-risk node-negative breast 
cancer (tumor size > 1 cm), having a left ventricular ejection fraction ofP55% and without 
important cardiovascular risk factors, regardless of age (LoE Ia). A subgroup analysis of 
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the HERA trial 
69
 demonstrated that women below the age of 35 derive the same benefit 
from one year trastuzumab as the overall population. 
 
Adjuvant bisphosphonates 
 
Until definitive results of clinical trials are available, bisphosphonates should not be 
routinely used in the adjuvant treatment of young women with breast cancer to improve 
disease outcome, (LoE IV). In the setting of combined endocrine therapy alone (i.e. LHRH 
agonist in combination with tamoxifen or aromatase inhibitor), there are data suggesting 
that zolendronic acid improves disease-free survival and maintains bone mineral density 
in pre-menopausal women.
70
 
 
 Metastatic breast cancer 
 
For this section, we have considered women with metastatic disease diagnosed before 
the age of 40. The treatment of metastatic breast cancer (MBC) should be discussed 
within the multidisciplinary team and patient preferences should always be taken into 
account. As recommended for early breast cancer, also in the metastatic setting, age 
alone should not be a reason to prescribe more aggressive therapy. There are few proven 
standards of care in MBC management overall 
71
 and even fewer in young women. 
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Therefore, inclusion of patients in well designed, independent, prospective randomized 
trials must be a priority whenever available. Whenever feasible the tumor should be 
tested for confirmation of diagnosis, histology and biology, especially in case of late 
relapse. Local treatment in case of isolated single visceral metastasis should be discussed. 
The specific psychosocial issues related to metastatic breast cancer in young women (i.e. 
information to family/ children, job and social insurance) should be addressed in a 
multidisciplinary setting. Research on age-related quality-of-life issues and supportive 
interventions should be a RESEARCH PRIORITY
72
. 
In endocrine-responsive metastatic breast cancer, most studies addressing the 
combination of endocrine treatment and chemotherapy showed an increased response 
rate or an increased time to progression but no improvement in overall survival
73
. This is 
in contrast to the early breast setting where combination of tamoxifen with 
chemotherapy was found to be detrimental and hence sequential use is recommended. 
Trials examining concurrent versus sequential treatment with endocrine therapy and 
chemotherapy need to be conducted. In addition, endocrine therapy can frequently be 
used as maintenance treatment after obtaining the maximum benefit from chemotherapy 
(LoE expert opinion). However, trials clearly evaluating the role of maintenance therapy 
for MBC (be it endocrine, biological or cytotoxic) are urgently needed (RESEARCH 
PRIORITY). 
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Endocrine therapy for advanced disease 
 
Endocrine therapy is the preferred option for hormone receptor-positive disease, unless 
there is concern or proof of endocrine resistance (i.e. early relapse under adjuvant 
endocrine therapy) or need for rapid disease and/or symptom control. In young patients 
with hormone receptor-positive or hormone receptor unknown metastatic breast cancer, 
tamoxifen in combination with suppression/ablation of ovarian function is the first-line 
endocrine therapy of choice (LoE IA)
74
. Aromataze inhibitors together with ovarian 
suppression/ ablation can be considered after progression on tamoxifen  } ovarian 
suppression/ablation (LoE IIB)
757677
. Fulvestrant has not yet been studied in pre-
menopausal women and specific studies are needed (RESEARCH PRIORITY)
78
. 
 
Chemotherapy for advanced disease 
 
Therapeutic recommendations should not differ from those for older women with the 
same disease characteristics and extent Young age by itself is not an indication to 
prescribe combination chemotherapy over sequential use of monotherapy. The fact that 
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young women tolerate chemotherapy better than their older counterparts should not be 
a reason to prescribe more aggressive regimens. 
 
Biological therapy for advanced disease 
 
Therapeutic recommendations should not differ from those for older women with the 
same disease characteristics and extent. 
 
Treatment of specific sites of metastases 
 
- Bone. 
 Therapeutic recommendations should not differ from those for older women with the 
same disease characteristics and extent. 
-Brain.  
Young age has been associated with an increased risk of brain metastases despite clinical 
and pathologic characteristics predicting for CNS recurrence often overlap with factors 
that indicate an increased risk for general metastatic dissemination (i.e. young age, ERand 
PR-negativity, high proliferation and genomic instability).
79
 
80
 Therapeutic 
recommendations should not differ from those for older women with the same disease 
characteristics and extent. 
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Palliative and terminal care 
 
The problems faced by young women at a palliative setting are different and should be 
addressed specifically (for example those related to her children and spouse). 
 
Treatment of locoregional relapse 
 
Young age per se is a risk factor for local relapse (LoE IA). The recommendations for young 
women do not differ from those for the general patient population. In case of a local or 
regional relapse, the tumor should be tested for confirmation of diagnosis, histology and 
biology. An isolated local recurrence after breast-conserving treatment should be 
preferably treated by mastectomy to obtain a R0 situation (LoE IC). Even if tumor free 
margins can be obtained by a second breast conserving operation, a disadvantage in 
overall survival as well as in local tumor control cannot be completely ruled out. A second 
breast conservation is therefore an individual decision after an informed decision making 
process. In a curative situation, a R0 situation must be obtained (LoE IIA). The role of 
surgery for locoregional relapse in patients with additional distant metastasis has not yet 
been completely clarified. An isolated thoracic wall recurrence should be preferentially 
treated by surgery and adjuvant radiotherapy, whenever possible (LoE IC). 
Systemic treatment for a completely excised locoregional recurrence should be discussed 
in a multidisciplinary team. Although local relapses are more frequent in women of young 
age at initial diagnosis, there are no specific data to guide treatment choices at the time 
of local relapse. Decisions on adjuvant systemic treatment after local relapse should be 
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influenced both by the initial biology and prior therapy, as well as by the biology of the 
relapse and the disease-free interval (LoE III). 
Systemic treatment for a completely excised locoregional recurrence should be discussed 
in the multidisciplinary team. So far, only the benefit of an additional endocrine therapy 
has been proven, and this treatment can therefore be recommended (LoE I). There is less 
data on the added value of chemotherapy in this setting, and randomized trials in this 
setting have been very difficult to run. Patients with a HER-2 positive local recurrences 
who have not received trastuzumab before or whose primary tumor was HER-2 negative 
(trastuzumab naive patients) should receive trastuzumab for one year in this “pseudo-
adjuvant” situation (LoE expert opinion). 
Patients with a primary inoperable local relapse should receive systemic therapy to 
improve operability and increase the chance of tumor free margins (LoE III). 
 
Locally advanced and inflammatory breast cancer 
 
Inflammatory breast cancer is slightly more frequent in young women, especially in 
women of African descent in the United States and in North African countries. 
Mean age at onset of inflammatory breast cancer in registries in western countries is 55 
(as compared to 62 for non inflammatory cases)
81
. Inflammatory breast cancer in young 
women does not appear to be linked to the constitutional genetic background. 
Since there are no data to indicate a different biology or a different prognosis
82
 the 
management of inflammatory breast cancer in young women should be the same as in 
the older breast cancer population. 
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13. Imaging and clinical follow-up of patients with breast cancer 
 
In women treated for sporadic breast cancer by breast-conserving surgery and adjuvant 
therapy, the risk of ipsi- or contra-lateral recurrence after 10 years is low at about <5%. 
Young age represents an unfavorable factor in terms of clinical outcomes. In fact, for 
women diagnosed at the age of 40 years or less, the risk of a local recurrence at 5 years is 
equal to 10%. Conversely, in patients treated by mastectomy, the risk of local relapse is 
not affected by the age at diagnosis. 
83
 
84
 Because the risk of ipsi- or contra-lateral relapse 
is constant over time, at least for 14 years, routine long-term follow up is 
recommended
85
. 
In terms of imaging, annual mammography (followed by ultrasound depending on breast 
density and/or presence of post-surgical and post-radiotherapy changes) represents the 
standard of care for follow-up of patients treated by breast-conserving surgery. However, 
a study on accuracy and outcomes of screening mammography in 58,870 women with a 
personal history of early-stage breast cancer showed that in patients under 40 years the 
risk of a second breast cancer within 1 year of screening is around 2% with respect to 0% 
of those without a personal history of breast cancer. The same study demonstrated that 
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screening mammography in younger women detects early-stage second breast cancer but 
shows lower sensitivity (51% in patients <50 years versus >64% in those P50 years) and 
higher interval cancer rate (7.5/1000 screens in patients <50 years versus >3.7/1000 
screens in those P50 years).
86
 Ultrasound could represent the first imaging modality after 
clinical examination in patients treated by mastectomy. Diagnostic performance of 
ultrasound in the identification of a relapse after mastectomy is higher than that of 
clinical examination (91% versus 79%) and mammography (91% versus 45%).
87
 As in older 
women, there is not enough evidence to support the routine use of MRI in following up 
young patients treated for sporadic breast cancer. In particular, there are no trials 
demonstrating improved prognosis after early detection of a recurrence by MRI. 
Currently, MRI examination may be useful if conventional imaging results are inconclusive 
for the differential diagnosis between scar and recurrence and where a needle biopsy 
cannot be performed. However, MRI imaging should be the first choice in breast cancer 
for patients at high genetic-familial risk.
88
 Regional nodal recurrence is not a frequent 
condition and occurs in only about 1–16% of patients with prior breast cancer. It is related 
to poor prognosis. Clinical examination and mammography show a high false negative 
rate in the evaluation of the axillary or supraclavicular region. A large retrospective study, 
evaluating 1817 patients after breast-conserving surgery demonstrated that ultrasound is 
useful in the identification of nodal recurrence in asymptomatic subjects, with an 
accuracy approaching 99%.
89
 In this study, the false negative rate of ultrasound was 
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significantly lower compared to that of clinical examination and mammography (23% 
versus 39% and 23% versus 100%, respectively). 
 
Imaging Procedures  
 
All breast units carrying out screening, diagnostic or assessment work must be in 
possession of local imaging protocols agreed by and made available to all clinic staff and 
forming part of the local QA manual, which should be based on national or European 
documents, containing accepted and published values.  
Mammography and ultrasound either alone or in combination remain the primary 
diagnostic imaging methods used for the breast. Protocols should be in place to 
discourage inappropriate referrals for breast imaging, e.g. breast pain, and to ensure that 
women with symptoms highly suggestive of breast pathology, e.g. a lump or skin / nipple 
dimpling or distortion have access to urgent investigation. Women with a family history of 
breast cancer should be referred to a specialist clinic with access to further genetic 
counseling should this be considered necessary.  
If mammography is required, a two view examination should be performed using the 
standard lateral oblique and cranio caudal projections. The use of mammography prior to 
the age of 35 is of limited diagnostic use and carries a higher theoretical risk from ionizing 
radiation. Mammography in this age group should only be used in particular 
circumstances such as a strong clinical suspicion of malignancy and when specifically 
authorized by the radiologist in charge. Where clinical findings are sufficiently suspicious, 
it may be advantageous to carry out oblique mammographic views in this age group to 
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search for radiological signs which may be relatively subtle to demonstrate 
sonographically , e.g. distortion or microcalcification.  
Ultrasound is the initial diagnostic method of choice if breast imaging is required below 
the age of 35. Other imaging techniques such as magnetic resonance imaging (MRI) of the 
breast have specific indications and do not form part of the initial diagnostic investigation 
at present (see resonance imaging section). If a woman complains of, or is found to have 
a discrete mass or other significant clinical sign in her breast which is not demonstrable 
mammographically, it is essential that she be referred for an ultrasound examination as 
part of standard triple assessment procedures. This will reduce the possibility of missed 
malignancy with negative mammography. Even if a clinical mass is demonstrated 
mammographically, ultrasound examination is still advised in order to further 
demonstrate imaging characteristics of the mass, or possible tumour extent, multi-
focality and axillary node enlargement in cases of malignant disease. In women with a 
positive finding on breast MRI, but an initially negative ultrasound examination, a focused 
second look breast ultrasound may be helpful in a substantial number of cases. The 
primary requirement of ultrasound investigation is to provide an image of good contrast 
and resolution, and a high level of anatomical representation. Additional ultrasound 
techniques such as Doppler imaging, blood pool imaging, 3D and 4D analysis, 
elastography (strain imaging) and panoramic representations may further enhance 
diagnostic information but have not yet been proven necessary for basic diagnosis.  
Mammography is associated with a variable false negative rate in the order of 10% - 20%, 
but this may be as high as 50% if the image quality is compromised for any reason 
including the age of the patient and the density of the breast. Assessment of 
microcalcification is likely to require magnification views, and these should be performed 
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in orthogonal projections, i.e. true lateral and cranio caudal in order to maximize the 
diagnostic information available. Initial work up of asymmetries, distortion and possible 
masses will require further views to be performed which may include paddle compression 
spot views, although it should be appreciated that the use of paddle compression may 
prove unhelpful and even misleading in cases where breast cancer presents as subtle 
asymmetries or an area of increased density.  
For many years digital mammography has had an established role for rapid spot-view 
imaging in stereotactic procedures. There is now increasingly widespread use of full-field 
digital mammography (FFDM) although clinical comparative and logistical evaluations are 
underway, the largest being the ACRIN, (DMIST) trial in the United States. The technique 
is known to have high image quality and is likely to become established due to multiple 
current advantages such as image manipulation, transmission and data display. On-line 
computer aided detection is available, and shown to provide advantages under certain 
conditions. FFDM in the majority of cases obviates the need for analogue microfocus 
magnification views of microcalcification, as on-screen magnification normally provides 
sufficient detail in order to base a clinical decision as to whether to proceed to tissue 
sampling techniques. FFDM also carries potentially significant advantages for 
technological developments such as tomosynthesis dual energy techniques and 3D 
reconstruction. As in the reading of film screen mammography, and possibly of even 
more importance, sufficient care must be given to ensure low incident light levels in the 
reporting room as the light output of the monitors is considerably less than a 
conventional x-ray viewing light box.  
Women with breast implants should be advised that these may significantly reduce the 
efficacy of subsequent mammography and that mammographic imaging should be 
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performed in clinics where ultrasound is available as it may frequently be required as an 
additional imaging technique. Magnetic resonance imaging is now recognized as the 
method of choice for investigating significant abnormalities in the breast in the presence 
of implants and for the assessment of possible intracapsular or extracapsular implant 
rupture.  
It is preferable to perform clinical examination prior to any image guided interventional 
sampling procedure so that subtle clinical signs are not disturbed by haematoma 
formation. For similar reasons it is preferable to perform any necessary basic imaging 
procedures such as mammography/ultrasound prior to any clinically guided sampling. If 
facilities and staffing allow, it may be logistically advantageous to perform sampling of 
clinically palpable lesions under image guided control in order to have visual confirmation 
of accuracy.  
Communication at all times is an essential part of the process and this must exist between 
the members of the imaging team e.g. radiographer/radiologist, as well as with the 
patient and the referring clinician. It is still the case that a number of breast cancers fail to 
be detected each year due to insufficient attention being paid to the symptomatic details 
being provided by the patients. 
 
 Diagnostic Imaging Unit 
The end point of the Diagnostic Imaging Unit is to correctly identify and classify imaging 
characteristics, and should not include further formal assessment with tissue/cytology 
sampling, with the exception of simple cyst aspiration. Further investigations should be 
performed at or in conjunction with a specialist breast assessment unit as laid out in the 
next section. This will ensure that cellular or tissue samples are analyzed by a trained and 
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recognized pathologist adhering to pathology quality assurance requirements. Feedback 
from the result of any such further investigations should be made available to the 
diagnostic unit for completion of the quality process. 
 
Mammography Equipment 
 
Dedicated mammographic and film processing equipment must be available with the 
facility to produce low dose with high contrast and spatial resolution examinations. An 
adequately high optical density is required for satisfactory image interpretation due to 
the proven relationship between optical density and small cancer detection rates
90
. 
Equipment should be up to date, of recognized manufacturer, suitable for its purpose, 
and subject to regular maintenance and quality control checks as laid out in chapter 2 of 
the 4
th 
edition of the European guidelines for quality assurance in breast cancer screening 
and diagnosis. For example it is not suitable to use a mammography machine without a 
foot operated compression system. All equipment in the unit must be subject to regular 
radiographic quality control checks and performance tests by a medical physicist suitably 
trained and experienced in mammography. Consistent breaching of quality control levels 
should lead to suspension of the equipment from use by the nominated person charged 
with the overall responsibility for quality assurance of the unit. 
The following are essential targets to be achieved; fuller requirements are laid out in 
chapter 2 of the 4
th 
edition of the European guidelines for quality assurance in breast 
cancer screening and diagnosis.  
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Targets  
Analogue targets  
High contrast/spatial resolution > 12lp/mm  
Optical density 1.4 – 1.9  
Mean glandular dose for standard breast per film <2.5mGy  
Daily processor control maintenance 100%  
Digital targets  
Contrast – to – noise ratio sufficiently high  
Mean glandular dose for standard breast < 2.5mGy  
Weekly homogeneity check  
Regular monitor check 
 
Ultrasound equipment 
 
Breast ultrasound should only be carried out by members of medical staff specifically 
trained and experienced in this procedure. It should not be carried out by General 
Practitioners, gynecologists, surgeons, radiologists, or radiographers who have not 
undergone such specific training and who do not participate in regular performance or 
audit of this activity. It is regarded as best practice that whenever possible the ultrasound 
examination should be carried out by a trained and specialist radiologist. The operating 
frequency of the ultrasound machine must be at least 7.5 MHz, and should preferably 
operate at 10 MHz or higher. Suitable recording facilities for sonographic images must be 
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available and used to record all significant findings with images clearly annotated to show 
side, size, depth and position of the lesion.  
 
 
 Basic Requirements of a Diagnostic Mammography Unit  
 
Ultimately it is hoped that all clinics offering breast diagnostic services will be subject to 
accreditation/certification procedures. Until that time the following criteria are proposed 
in line with the Certification Protocols (chapter 11 of the 4
th 
edition of the European 
guidelines for quality assurance in breast cancer screening and diagnosis).  
The following basic criteria will be required from a Diagnostic Mammography Unit, which 
should:  
A. Perform at least 1,000 mammograms per year.  
B. Have dedicated equipment specifically designed for application in diagnostic 
mammography and ultrasound e.g. mammography system with magnification ability and 
dedicated processing, and be able to provide adequate viewing conditions for 
mammograms.  
C. Comply with the physico-technical protocol in chapter 2 of the 4
th 
edition of the European 
guidelines for quality assurance in breast cancer screening and diagnosis.  
D. The radiographer, technologist or other member of staff performing the mammographic 
examination must have had at least 40 hours of training specific to the radiographic 
aspects of mammography and regularly participate in External Quality Assessment 
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Schemes where available and radiographic update courses. This person must also take 
the lead in the radiographic aspects of quality control.  
E. Employ a trained radiologist, i.e. a person who has had at least 60 hours of training 
specific to mammography and who in volume requirements reads at least 500 
mammograms per year.  
F. Keep a record of mammogram results and monitor numbers of women referred for 
further assessment.    
G. Provide feedback of further assessment outcomes to the unit radiologists. 
 
Volume requirements as stated in this section and the following section are regarded as 
the absolute minimum required to allow the production of adequate diagnostic quality 
images. Greater number may not guarantee higher quality, but are more likely to be 
associated with a significantly higher level of professional skill and physico-technical 
excellence. For this reason, higher volume throughputs are strongly recommended, there 
being scientific data demonstrating improved performance of radiologists’ reading in 
excess of 2000 mammograms per annum
91
 
In all cases a mammogram refers to a full set of mammograms performed on a woman, 
and should not under any circumstances for the purposes of numerical advantage be 
counted in terms of individual mammographic exposures. 
Diagnostic classification 
A simple five-points classification system should be used as described below to convey an 
overall impression (which is auditable) in addition to the normal descriptive methods.  
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Radiology  
R1 Normal/benign  
R2 A lesion having benign characteristics  
R3 An abnormality present of indeterminate significance  
R4 Features suspicious of malignancy  
R5 Malignant features  
While this system is sufficient for most working purposes, if desired, use can be made of 
the ACR BIRADS system which is a more complex but precise classification in terms of 
percentage likelihood 
92
  
Ultrasound  
U1 Normal/benign 
U2 A lesion having benign characteristics  
U3 An abnormality present of indeterminate significance  
U4 Features suspicious of malignancy  
U5 Malignant features  
Fine Needle Aspiration Cytology  
C1 Inadequate for diagnosis  
C2 Benign epithelial cells  
C3 Atypia probably benign  
C4 Suspicious of malignancy  
C5 Malignant  
Core Biopsy/Histology  
B1 Unsatisfactory/Normal breast tissue  
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B2 Benign  
B3 Benign but of uncertain malignant potential  
B4 Suspicious of malignancy  
B5 Malignant  
A negative or benign clinical examination must not be allowed to downgrade the 
importance of suspicious imaging or cyto/histological findings unless the radiologist or 
pathologist has been fully consulted. 
 
 The Place of Magnetic Resonance Imaging in Breast Diagnosis  
 
As previously stated MRI is not yet part of the initial diagnostic workup. The full role and 
place of MRI in breast diagnosis is still being evaluated, however the procedure is 
becoming more established and widely used. It already has an established role in the 
evaluation of breast implants and in the differentiation of recurrent disease from post 
surgical scarring, where it has a very high negative predictive value. There is however no 
evidence at present for its usefulness or cost effectiveness as routine follow-up after 
breast cancer surgery.  
MRI is of proven value in helping to establish the degree of disease present where 
malignancy is already established or highly likely in dense breasts or tumours having a 
likelihood of multi-focality, multicentricity or bilaterality. It has also been shown to have a 
high sensitivity in the detection of malignancy in younger women of high risk groups. MRI 
is of value in assessing the extent of residual disease following induction chemotherapy 
prior to surgical treatment. Other indications may include looking for the site of an occult 
primary tumour , or establishing whether a residual tumour is present in the breast 
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following an apparent failure to surgically excise a tumour. The assessment of axillary 
lymph node recurrence, also clinical or mammographic abnormalities difficult to assess by 
conventional means are other potential uses. It is recommended that MRI of the breast is 
best carried out in units with sufficient experience, having the necessary equipment and 
expertise to proceed to MR guided biopsy for lesions that are occult on conventional 
imaging following second look ultrasound. 
 
 Staging and Follow-up  
Bone scanning, liver ultrasonography and chest radiography are commonly used in 
patients with newly diagnosed breast cancer as part of baseline staging. However in the 
absence of symptomatic disease, this routine diagnostic work-up may not be cost-
effective, or justified. Multiple studies of this strategy have shown early detection of 
asymptomatic metastases, but such early detection does not affect quality of life or 
survival. Most recurrences are detected in cases with an advanced stage at diagnosis. 
These findings indicate that a complete diagnostic work-up to detect metastases is 
unnecessary in the majority of patients with newly diagnosed breast cancer, whereas it 
may be indicated for patients with advanced disease (stage III-IV).  
Imaging should be used to diagnose women with symptoms suggestive of metastatic 
disease. Women with pain suggestive of bone metastases should have plain films initially. 
If such films are normal and symptoms persist, bone scintigraphy and/or MRI can be used. 
MRI can be very useful in differentiating osteoporotic vertebral collapse from metastases. 
Solitary bone lesions in the absence of visceral metastases will often require bone biopsy 
to confirm metastatic disease, especially in patients with a primary tumor having good 
prognostic features. Symptoms suggestive of lung metastases should be investigated 
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using a chest x-ray initially and CT if required. Abnormal liver function and/or abdominal 
pain can be investigated using ultrasound or CT.  
Patients with confirmed metastases at one site will require radiological staging of their 
disease for two reasons. Firstly, to assess the burden and sites of metastases as this will 
affect both prognosis and therapeutic options. Secondly, assessable lesions need to be 
identified to allow assessment of response to systemic therapy. This will allow cessation 
of expensive and toxic therapies which are not working and make possible timely 
institution of second line therapies.  
Periodic diagnostic assessment, currently referred to as follow-up, is a common practice 
in breast cancer patients after the completion of primary treatment.  
Follow-up may have different aims:  
• Early detection and early treatment of recurrent disease, either local or metastatic. 
Recurrences are concentrated in the first three years and then having a stable 1-2% yearly 
incidence. Breast cancer is a systemic chronic disease: the risk of dying from it remains 
higher as compared to healthy subjects up to 30 years after primary treatment. About 
50% will recur during their lifetime.  
• Surveillance of the contralateral breast with a 5 times higher risk of developing a 
metachronous cancer which may have an independent impact on prognosis  
• Improvement of quality of life by reassuring the patient  
• To monitor the status of the disease  
• To monitor and prevent negative side effects of treatment (e.g. endometrial cancer in 
Tamoxifen users, or osteoporosis in premenopausal women undergoing hormone 
deprivation)  
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Each of these aims has been the object of discussion over time, based on several 
conflicting experiences.  
No definitive evidence is available thus far that early detection and treatment of 
recurrence may have a favourable impact on prognosis. It is well known that earlier 
detection is associated with less extensive recurrence and that limited recurrent tumour 
burden is associated with prolonged survival, but this is not sufficient to demonstrate a 
real benefit as improved survival might be simply due to diagnostic anticipation (lead 
time) with no real postponement of death. In a Randomized Controlled Trial published in 
1994
93
 , intensive follow up [Chest X ray, liver echography, radionuclide bone scan, 
mammography(MX)and physical examinations (PE)every 6 or 12 months] showed no 
effect on mortality at 5 and 10 years, when compared with minimal follow-up( PE and MX 
only ).  
The evidence of long term cure of limited as compared to extensive local recurrences 
suggest a possible favorable prognostic impact of early detection of these events, 
particularly as regards recurrences in the axilla and in the surgical scar or conserved 
breast. Such events are likely to become more frequent with the adoption of conservative 
therapeutic options as tumorectomy and sentinel node technique. Although no definitive 
evidence of a favorable prognostic impact of early detection of local recurrences is 
available, the presumed benefit and the fact that early detection in the asymptomatic 
phase is achieved by palpation and mammography, which are included in a 'minimalist' 
follow-up approach , justifies such a current practice.  
Early detection of primary breast cancer may reduce breast cancer mortality, as shown by 
several controlled studies of screening by mammography. There is no reason why this 
                                                           
93
 Rosselli del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P,Distante V: Intensive Diagnostic Follow-upafter 
Treatmentof a PrimaryCancer.A RandomizedTrial.JAMA1994; 271: 1593-7 
 Management of a High Quality Comprehensive Breast Center 
126 
 
should not occur also for contralateral metachronous breast cancer, although the 
magnitude of such an impact is certainly reduced for the concurrent prognostic effect of 
first breast cancer. A recent report has shown a higher risk of breast cancer death for 
subjects developing a symptomatic, rather than an asymptomatic metachronous 
contralateral breast cancer detected by periodic mammography
94
. Periodic 
mammography (often with a higher frequency as compared to screening of healthy 
subjects) is currently performed even in a 'minimalist' follow-up approach.  
Several circulating markers have been tested to detect breast cancer, and generally have 
been abandoned for routine testing. Two arguments argue against the use of markers in 
clinical practice. First the imperfect sensitivity and specificity, second the current lack of 
curative therapy for metastatic breast cancer.  
At the moment most of the International Societies do not recommend the use of routine 
tumour markers in the surveillance of breast cancer as there is good evidence not to 
include blood work (as well as diagnostic imaging) as part of screening for distant disease  
In conclusion follow-up of breast cancer patients is standard practice all over the world. 
The investigation of distant metastases aimed at early detection and treatment seem to 
have no prognostic impact, for the present state of art of diagnosis and treatment, but 
minimalist follow-up, based on periodic physical examination and mammography 
(conserved and/or contralateral breast), seems a reasonable option as it's possible 
advantages in terms of prognosis and psychological impact have never been denied.  
New prospective studies of follow-up efficacy should concentrate on new protocols 
suggesting higher sensitivity and/or specific subgroups promising higher therapeutic and 
cost-effectiveness potential. 
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14. Surgical Aspects  
Young age is an independent risk factor for increased local recurrence after breast 
conserving surgery and radiotherapy without affecting overall survival.
95
 
96
Some of the 
histopathological characteristics such as larger size, higher grade, presence of peripheral 
extensive intraductal component, vascular embolies and lymphoid stroma have been 
related to a higher risk of local recurrence. Nevertheless, surgical treatment of young 
patients presenting with invasive cancer – while being tailored to the individual patient – 
should in general not differ from that of older patients. Breast conserving surgery 
followed by radiotherapy offers the same survival benefits as modified radical 
mastectomy in women with stage I or II breast cancer 
97
 
98
 and should therefore be 
considered as the first option whenever suitable This may be particularly relevant for 
young women with breast cancer. Modern breast conserving surgery is aimed to remove 
the cancer while excising the smallest possible volume of tissue. Besides, and especially in 
young women, aesthetic outcomes and concept of female identity need to be taken into 
account. Skin-sparing and nipple-sparing mastectomy techniques seem to be ideal 
options both from an oncological and a cosmetic point of view. 
99
 Oncoplastic repair 
techniques should be offered to patients treated by breast conserving surgery in order to 
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maximize cosmetic results whenever an obvious postoperative asymmetry can be 
estimated (LoE IC). Immediate breast reconstruction after mastectomy offers the same 
survival benefits as mastectomy without reconstruction (LoE IC). The options of 
immediate breast reconstruction should be discussed prior to surgery, ideally by a 
multidisciplinary team, in order to consider the issues related to possible indications for 
post-mastectomy radiotherapy. In young women with the diagnosis of either invasive 
disease or pre-invasive lesions, who are not BRCA mutation carriers, there is no evidence 
for improved overall survival by performing risk-reducing bilateral mastectomy. The risk 
for contralateral disease in young women with a family history who are not BRCA carriers 
does not seem to be substantially increased. 
100
 Nevertheless, if, after receiving proper 
and thorough information based on the available data and on an appreciation of the 
possible surgical complications and consequences, the patient still shows a strong 
motivation to undergo prophylactic surgery, this preference should be respected. In this 
situation, adequate time should be given to the patient to allow the proper 
understanding of all information and to avoid “rush decisions”. 
 
 Pre-operative localization  
Lesions that are either impalpable or difficult to locate with certainty on clinical 
examination will require some form of pre-operative localization marking procedure 
provided by the radiologist .  
In order to limit the number of unnecessary biopsy procedures performed, it is 
recommended that the ratio of benign to malignant surgical excision biopsies performed 
for diagnostic purposes should not exceed 0.5:1. Already diagnosed benign lesions and 
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lesions removed due to patient choice are excluded. For cosmetic reasons it is important 
to minimize the extent of benign biopsy for impalpable lesions, and at present the most 
suitable discriminatory factor used is the weight of the specimen. Over 90% of diagnostic 
biopsies for impalpable lesions which subsequently prove benign should weigh less than 
30 grams.  
When breast cancer has been diagnosed and the patient agrees to conservative surgery, 
localization procedures are mandatory. The target is the full excision of the tumour with 
uniform margins. In the past, the standard approach to tumour localization has been 
hook wire or dye localization. An ultrasound or mammographic - guided hook wire is 
inserted in the breast and placed by the radiologist within one centimeter of the lesion, if 
possible in at least 90% of cases, or a second wire should be inserted. In cases of 
segmental microcalcification it may be advantageous for the radiologist to bracket the 
extent of the calcification with guide wires to allow complete surgical excision. The 
surgeon must be provided with a full and accurate description of the procedure 
performed and a precise report of the relative placement of the wire compared to the 
lesion. Relevant images correctly marked should also be provided.  
The hook-wire method is particularly useful for deep lesions mainly in dense breasts 
where it can be anchored more securely. The disadvantage is that this procedure must be 
carried out shortly before surgery and it requires accurate planning. The hook wire may 
move from its original position, this happens more frequently in fatty breasts. For dye 
localization, it is important to use a sterile charcoal suspension that does not diffuse into 
the surrounding tissue and that stays in for a long time. The injection of the charcoal is 
guided by mammographic, stereotactic or ultrasound examination. The trace goes from 
the lesion to the skin where a small spot is evident.  
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The indications for this method are the same as for the hook-wire but the advantage is 
that it can be carried out at the time of cytological or micro histological pre-operative 
diagnosis.  
A more recent method for localization of non-palpable tumours is called ROLL (radio-
guided occult lesion localization) 
101
. Before the operation, the patient is injected with 0.2 
- 0.3 ml of 99 mTc - labelled colloid particles of human serum albumin into the centre of 
the suspicious lesion under stereotactic or ultrasound control. The excision biopsy is 
performed using a gamma detecting probe. The site of the lesion shows the maximum 
radioactivity. Margins of resection are defined where radioactivity falls sharply. After 
excision, the probe is used to check the resection bed. ROLL is particularly recommended 
in micro calcification clusters, in parenchymal distortion and in single opacities. A 
technique of intra-operative ultrasound guided excision of non-palpable breast cancer is 
also feasible for patients with ultrasound detectable lesions, with results that are 
comparable to those reported with other methods.  
When the lesion is visible on x-ray, specimen radiographs must be available in, or in very 
close proximity to the operating theatre so that confirmation of excision of the lesion can 
be confirmed without delay and prior to skin closure. Surgical clips should be used for 
orientation. Successful excision of impalpable lesions is therefore a combination of 
surgical as well as radiological skill and the proportion of impalpable lesions successfully 
excised at the first operation and not requiring a second operation should be in excess of 
90%. Specimen radiographs must also be made available to the pathology department. It 
is accepted that the only true reflection of excision adequacy is the subsequent rate of 
local recurrence.  
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Loco-regional therapy in high-risk women 
 
Management of young high-risk women with breast cancer is very complex and should 
therefore be performed within specialized centers. The evidence regarding the necessity 
of ipsilateral mastectomy is inconclusive in this subset of patients 
102
 
103
and, therefore, 
breast conservation remains a suitable option after a thorough discussion with a patient 
motivated to retain her breast. Radiation does not lead to increased toxicities in BRCA 
mutation carriers
104
. In known BRCA mutation carriers, risk reducing surgery, such as 
bilateral mastectomy and oophorectomy, needs to be discussed as part of the initial 
treatment concept. Rapid BRCA testing is indicated if knowledge of the mutation status 
would impact on the BC treatment plan (e.g. radiotherapy/reconstruction). Nevertheless, 
if the patient needs more time to decide about any possible prophylactic surgery or if a 
rapid test is not achievable, stage-adapted treatment of the breast cancer should be 
performed while postponing any potential prophylactic procedure to a second stage. 
 Surgical treatment of the axilla 
Sentinel lymph node biopsy (SLNB) is, worldwide, considered to be the first choice of 
axillary staging in patients with early breast cancer. There is no evidence of an increased 
false negative rate or a worse outcome in young patients undergoing (SLNB). 
105
  In young 
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women, indications for (SLNB) are the same as in older patients. The procedure should be 
performed according to national and institutional guidelines and young age per se is not a 
reason to prefer axillary dissection over (SLNB). In pregnant patients with breast cancer, 
lymphoscintigraphy and (SLNB) can be performed as low injected doses are utilized and 
dosimetric studies confirm negligible effects on both the mother and the foetus. 
106
 
107
Nevertheless, the panel strongly recommends that management of pregnant patients 
with breast cancer is performed in specialized centers and involving the multidisciplinary 
team. Surgical management of patients with minimal Sentinel 
Lymph Node (SLN) involvement is still matter of debate. In particular, no data are 
available for this specific topic in young women. When isolated tumour cells are found in 
the SLN, general agreement is not to perform Axillary Lymph Node Dissection (ALND). At 
the moment, the trend is moving towards minimizing axillary surgery with sparing the 
axillary nodes even in the presence of micrometastases in the SLN. 
108
 Recent data from a 
randomized trial 
109
 enrolling patients of any age showed that ALND did not significantly 
affect disease-free or overall survival of patients with clinical T1–T2 cN0 breast cancer and 
at the most two positive SLN treated with lumpectomy, adjuvant systemic therapy and 
tangential-field whole breast irradiation. Therefore, avoidance of axillary dissection can 
and should be discussed even in young patients with involved SLN who will undergo 
breast conservation with whole-breast radiotherapy and appropriate systemic treatment. 
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 Adjuvant radiotherapy 
 
High quality standards are mandatory in order to minimize side effects and maximize 
benefits. This is particularly relevant in young women with their potential long-term 
survival. Treatment planning should be performed using CT scan imaging and three-
dimensional dosimetric systems. Doses to the breast and tumour bed should be 
homogenized within recommended tolerance margins, and doses to organs at risk (mainly 
ipsilateral lung, heart and contralateral breast) should be kept below consensus 
thresholds in all instances. In patients with early breast cancer, adjuvant irradiation is 
indicated after breast conserving surgery (LoE IA). Adjuvant chest wall radiotherapy after 
mastectomy should be offered to patients with early invasive breast cancer and a high 
risk of local recurrence including where there are four or more positive axillary lymph 
nodes or involved resection margins (LoE IA). Until data from a large ongoing randomized 
trial 
110
 become available, radiotherapy after mastectomy should be discussed with 
patients with 1-3 positive nodes (LoE IA). Young patients should be informed about the 
high local recurrence risk if radiotherapy is avoided
111
 and about the evidence for the 
advantages of radiotherapy regarding reduction of local recurrence and improvement in 
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overall survival.
112
 This must be balanced with information on the potential long-term 
toxicities. Internal mammary chain irradiation should be discussed on the basis of clinical, 
histopathological and radiological findings in the multidisciplinary team (LoE expert 
opinion). The target volume of percutaneous adjuvant radiotherapy encompasses the 
entire breast and the adjacent thoracic wall. The dose amounts to approximately 50–50.4 
Gray fractionated in the conventional manner (1.8–2.0 Gray per fraction) with an 
additional local boost (LoE IA). Alternative fractionation regimes such as those utilising 
hypofractionation with a higher dose per fraction enabling the use of fewer fractions 
should – at the present time – be considered with caution as the randomized trials of 
hypo-fractionation included few younger women 
113
 (LoE IB). An additional boost to the 
site of local excision must be offered to young patients with early invasive breast cancer 
following breast-conserving surgery with clear margins and whole breast radiotherapy, 
particularly to those at high risk of local recurrence 
114
 (LoE IIA). Axillary radiotherapy 
should be discussed on an individual basis in the multidisciplinary team and will depend 
on surgical, histopathological and where available, radiological findings (LoE IA). Partial 
breast irradiation (PBI), by whatever method, is best delivered within the protocol of a 
clinical trial until the results of all current trials 
115
 are reported or are more mature. 
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Young age is a recognised risk factor increasing local relapse after mastectomy. 
116
 
Therefore, patients should be informed prior to surgery about the possibility of 
undergoing post-mastectomy radiotherapy in order to facilitate any necessary discussions 
with the plastic surgeon about options for immediate breast reconstructions and their 
potential limitations. Young age is one of the risk factors for involvement of the internal 
mammary chain (IMC). Evidence (LoE II) from retrospective generally under-powered 
series suggests that IMC radiation is an option. It will remain such until mature results 
from large clinical trials are available. However, side effects from IMC irradiation may be 
severe if high standards of radiotherapy are not followed and, in particular, radiation 
doses to the major vessels and coronary arteries must be kept to absolute minima. It is 
imperative that long-term side effects are carefully balanced against published benefits. 
 
 
The surgeon 
The surgeon is a member of the multidisciplinary team and should participate in regular 
multidisciplinary review for case management and audit purposes. The surgeon should be 
fully involved in the assessment of women and should always see and examine the 
patient before accepting her for surgery.  
It should be agreed surgical policy that mammography is carried out prior to breast 
surgery providing the woman is in an appropriate age group. Firstly as a matter of good 
practice to demonstrate the nature and extent of any disease that is identifiable, secondly 
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to ensure that full imaging information is available for interval cancer review should the 
women have previously attended a breast screening program.  
The surgeon should be discouraged from cutting specimens open after removal in theatre 
before sending them to pathology. All specimens should be marked and orientated 
according to recognized local protocols. The surgeon should ensure completeness of 
excision, which may be assisted by the use of two plane specimen radiography. At 
operation, the use of frozen sectioning is generally inappropriate, particularly in the 
assessment of clinically impalpable lesions. It may occasionally be justified to enable a 
firm diagnosis of invasive malignancy to be made in order to allow definitive surgery to be 
carried out in one operative procedure. In general terms surgeons should adhere to the 
principles laid out in staging and follow up section, and in particular the monitoring of 
surgical outcome measures as defined in surgical aspects section of the 4
th 
edition of the 
European guidelines for quality assurance in breast cancer screening and diagnosis. The 
surgeon should ensure that all data necessary for subsequent patient management and 
audit should be recorded including the size of any tumour, its grade, type, lymph node 
status and biological characterization. A suitably agreed minimum data set reporting form 
should be used.  
Targets  
Proportion of wires placed within 1cm of an impalpable lesion prior to excision  
Minimum Standard >90%  
Proportion of impalpable lesions successfully excised without recourse to second 
operation  
Minimum Standard >90%  
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Proportion of benign diagnostic biopsies on impalpable lesions weighing less than 30 
grams  
Minimum Standard >90%  
The rate of benign to malignant operations performed for diagnostic biopsy purposes  
Minimum Standard 0.5:1  
No frozen section performed if tumour diameter <10mm  
Minimum Standard 95% 
 
Sentinel Lymph Node Biopsy Procedures  
 
Sentinel lymph node biopsy has become an established technique, with sensitivity in 
excess of 90%. The technique can be used to allow avoidance of axillary clearance and 
possible associated morbidity in a number of women. Pre-operative axillary ultrasound 
may detect abnormal lymph nodes which can further be investigated by ultrasound-
guided FNAC. If this confirms involvement, the surgeon can immediately proceed to an 
axillary dissection. Identification can be made using an injection of a blue dye or 
radioisotope, either alone or in combination, which improves the identification rate. The 
technique requires close co-operation between the surgeon, radiologist, nuclear physicist 
and pathologist.  
The European Working Group for Breast Screening Pathology has described the 
formulation of guidelines for this procedure
117
 . Further reference should be made to the 
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pathology and surgery sections in chapters 6 and 7 of the 4
th 
edition of the European 
guidelines for quality assurance in breast cancer screening and diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Management of a High Quality Comprehensive Breast Center 
139 
 
 
15.  Pathology Quality Assessment Aspects  
 
Accurate pathological diagnoses and the provision of prognostically relevant information 
are essential to ensure proper patient management, program monitoring and evaluation. 
Each Specialist Breast Unit including a Diagnostic Breast Assessment Unit should have 
access to high quality pathology services provided by pathologists with special expertise 
in breast pathology.  
Pathologists providing a breast histopathology and/or cytopathology service should have 
had specialist training (see Chapter 10, Guidelines for Training in the 4
th 
edition of the 
European guidelines for quality assurance in breast cancer screening and diagnosis) and 
participate in a continuing educational program. They should follow recommended 
reporting guidelines and diagnostic protocols and should participate in relevant External 
Quality Assessment schemes.  
The pathologist is a key member of the specialist multidisciplinary team and has a primary 
role in the pre- and postoperative conferences. Patient management is largely based on 
the pathological findings. They should be sufficiently detailed and accurate.  
The pathologist should have a general knowledge of:  
1.  The principles of breast cancer treatment: surgery, radiotherapy and medical treatment  
2.  The principles of imaging of breast lesions,  
3.  The basic epidemiological aspects of breast cancer  
 
The pathologist should have special expertise in:  
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1.  The classification of malignant non-invasive and invasive lesions, and the assessment of 
relevant immuno-histochemical tests e.g. hormone receptor- and HER2-status,  
2.  The radiological and pathological correlation of benign and malignant lesions,  
3.  The optimal handling of surgical biopsy specimens, the use of specimen radiography and 
the assessment of the surgical margins,  
4.  The interpretation of needle core biopsy and fine needle aspiration cytology,  
5.  The interpretation of sentinel node biopsy samples.  
 
Specialist Breast Units and Diagnostic Breast Assessment Units deal with patients having 
palpable as well as non-palpable breast lesions. Requirements for histopathological 
assessment, reporting protocols and quality assurance for both types of lesions are 
practically the same, and are laid out in chapter 6 of the 4
th 
edition of the European 
guidelines for quality assurance in breast cancer screening and diagnosis.  
All pathology laboratories should be accredited according to national standards. 
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16. Weekly meeting of all disciplines in order to make and 
discuss decisions and results 
All breast units engaged in diagnostic or therapeutic surgical excision biopsy must ensure 
the formation of proper multidisciplinary teamwork involving the following personnel: 
Radiographer, radiologist, histo/cytopathologist, surgeon nurse counsellor. If treatment is 
involved, the team should include a radiotherapist/medical oncologist. In view of the 
importance of the management decisions taken in such meetings, it is crucial that the 
meeting is attended by senior professionals and that these issues are not delegated to 
junior members of the team.  
Before a woman is considered for surgical excision biopsy her case and results should 
have been discussed in the setting of a full multidisciplinary meeting. By so doing the 
surgeon will be best appraised of the likelihood of malignancy, the extent of abnormality 
on imaging and any discordant results which may have been obtained upon review of the 
case, which might lead to an alteration of surgical planning or management. Similarly all 
biopsy results should be discussed in a multidisciplinary audit setting to establish the 
nature of disease, its extent, completeness of excision and the appropriateness of the 
histology compared to the pre-operative diagnosis. Unexpected results should be 
discussed in this setting to establish their veracity, to confirm that the correct lesion has 
been excised and to provide a source of learning and experience.  
The results of discussions that have taken place during formal multi-disciplinary meetings 
should be recorded and documented for audit purposes. 
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17. Comparative overviews 
As there already exists scientific material, publications,  guidelines that have proved the 
utility of breast centers worldwide the aim of my thesis is not only presenting this format 
but also emphasize that the sanitary systems lacking of such format can not offer to their 
patients the proper treatment. 
I can bring to you several examples and I want to start with a sanitary system that lacks 
such format. In Albania does not exist a proper breast center, there is no continuity on 
following the patients from the diagnosis to the treatment and then to the followup. The 
diagnosis is made casually, sometimes because showering the patients realizes a nodule 
in her breast, sometimes because her relatives or the neighbor is having chemotherapy 
because of breast cancer, or just because in the film she watched the night before made 
her think of the eventuality of having a breast cancer. What I want to say is that there is 
no education for prevention of breast cancer or a proper screening program. And this is 
the first and according to me the most pain giving problem. 
Once causally diagnosed the breast cancer the patient finds herself in the situation where 
she has to decide the treatment option without having real information on what it is 
going to happen. Feeling hopeless, confused and seeking for answers almost all the 
patients find themselves trying to have second and third opininion, in a very short time 
they do at least three- or four mammograms and the same amount of ultrasound from 
different physicians. As we know imaging diagnosis is not only operator related but also 
the machine quality is also very important. To sum up these patients find themselves in 
the situation where they have to take decisions and nothing they have performed is any 
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help because the variables are a lot!!! Different operators, different mammograms and 
different specialist’s opinion make everything very difficult. For all these movements 
there is a loss in time, fatigue caused not only from the disease but also from all the 
movements and a lot of money because every cost is on the patient.  
Once reached in a decision which has raised the anxiety of the patient from the waiting 
time, from the fear caused from the treatment and the most important from the fear 
caused from the beast called cancer. As in Europe women are informed of the research 
done in this field, of the decreasing mortality, of the treatment alternatives breast cancer 
is not anymore the beast that causes just one thing, the death. So these women find 
themselves most of the time directly on an operating room without anyone supporting 
their fear and caring about the change that is happening in their lives.  
For most of these women despite the aggressivity that the treatment brings in their body 
their femininity dies the moment they enter that operating room. Even though it is not a 
radical mastectomy the psychological effect is totally the same. 
These are not the only licking points of the system; the follow up program is also 
unsuccessful. These patients are followed most of the time by doctors that don’t even 
know the history, that are not necessarily specialized in the disciplines that are part of the 
program. Even worse in some cases the patient neglects further examinations as 
unnecessary or very expensive. 
Discussing these points forms in front of my eyes just one picture- the lack of efficiency 
that such chaos in the sanitary system brings and the considering of the patient just as a 
body to treat regardless to feelings, life quality and the psychological-sexual sphere.    
I made a general picture without entering in details that are also very important. The 
solution of this disorganization, which is not caused because of the doctors lack 
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professional ability or patients ignorance, is creating a system that takes care of the 
patient in every step of their disease coarse. 
Another example I would like to bring is the halfway between the well functioning breast 
center and the system where such a format does not exist. In Turkey there exist breast 
centers in the biggest cities. Actually the format is conforming to all the guidelines but the 
problem is applying it. There is nothing wrong with the sanitary system, orientation and 
collaboration between the taking part disciplines, the real problem is the culture which is 
influenced from the misunderstood religion view. 
Being a woman in such cultures is very difficult; everything may seem a sacrilege   and 
approaching to a mostly male represented world such as medicine makes the early 
diagnosis almost a miracle. 
Having approximately 70% of the population living in rural zones makes information and 
the application of this format very difficult.  
I have frequented the principal centre of the country for the breast cancer treatment and 
until you start to frequent the ambulatory everything seems to be perfect because the 
patients reach to the treatment phase well informed and equipped with the 
documentation of the examinations performed in the same centre and have met all the 
doctors of the centre who have proposed the treatment and explained it in details. So it 
seems a very calm and peaceful place even though the tragic carrying of the cancer. 
The ambulatory is the place where you realize the real problem of the system. The 
decisional power of the women and their fear from the reality they find themselves. You 
realize that not only the culture but also the patients themselves underestimate their 
psychological shock caused by the change. There is no care about the esthetic result and 
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sometimes even though proposed by the plastic surgeon a plastic intervention is denied 
because considered too extravagant.  
The third example of this format I have studied is the Italian one. The one I have not only 
studied as a student, lived as an intern but also experienced as a patient. 
The breast centre in Italy is now a confirmed solution to the treatment of cancer. These 
centers not only have applied the European guidelines but often these guidelines have 
been a result of the research and improvement in the sanitary system in Italy, which has 
always been a country who has started initiatives of this kind thank to its valuable doctors 
and physicians. 
These centers have applied all the points that define a quality breast centre as I have 
largely explained in my work without underestimating anything. The patients here are 
fully followed not only to the narrow aim to cure cancer but taking care of all the 
problems that invade their life and their family. 
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Last but not least… 
18. …Supportive care for patients with breast cancer 
 Anxiety and Delays  
 
Delays at any stage of the diagnostic process may result in anxiety for the woman, which 
sometimes may be considerable. Targets should be set in terms of working days (w.d.) at 
every stage where delay may arise.  
Delay between mammography and result  
Minimum standard - <5 w.d.  
Delay between result of imaging and offered assessment  
Minimum standard - <5 w.d.  
Delay between assessment and issuing of results  
Minimum standard - <5 w.d.  
Delay between decision to operate and date offered for surgery 
Minimum standard - <15 w.d. Ideally <10 w.d.  
95% of women should receive full and adequate assessment in three appointments or 
less.  
90% of women with symptoms and signs strongly suggesting the presence of breast 
cancer should be seen within two weeks of referral, and agreed protocols should be in 
place to facilitate this.  
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Unnecessary distress may be caused not only by delays as listed above but also by failure 
of efficient communication between the diagnostic team and the woman. Failure to reach 
a definitive diagnosis due to imprecise methods of assessment also results in anxiety.  
If possible the radiologist should be present in the clinic at the time when a woman has 
her mammogram so that any necessary further investigation e.g. ultrasound examination, 
can be performed without delay. It is also important that full verbal information on the 
status of her investigations and diagnosis be given to the woman at suitably relevant 
stages throughout the diagnostic process. As far as possible the woman should be 
informed of the result of her examination before she leaves the clinic and of the need for 
any necessary further investigation to be performed.  
The failure of the assessment process to make a definitive diagnosis of either a benign or 
a malignant condition is an undesirable outcome of assessment and further increases 
anxiety. For this reason the use of early recall for a repeat examination at a time shorter 
than that normally specified for a routine follow up is to be avoided. Women must be 
informed of when to expect results and should be provided with written information at 
appropriate stages in the diagnostic procedure. However women should not be informed 
by letter or telephone of the likelihood of malignancy being present. Such information 
should be given verbally to her in the presence of a nurse counselor.  
Rapid diagnostic / one stop clinics  
There is considerable advantage to the formation of rapid diagnostic clinics, set up in 
breast units, where the diagnostic team may work together in a multidisciplinary setting. 
Women may receive a diagnosis and management plan in the quickest time possible, 
either during the same clinic, or having all necessary investigations at the same time and 
returning for results within 24 – 48 hours. Complex investigations such as MRI, if required, 
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may take longer to organize. The main advantages of this system are to reduce anxiety, 
and to provide a certain level of skill and teamwork not otherwise available. For this 
reason as previously recommended all women with discrete masses or significant signs or 
symptoms must be referred directly to a specialist breast unit, and not to a basic 
diagnostic unit. 
 
 
Psychological, gynecologist, nutritionist (and not only) support 
Even if breast cancer diagnosis is a difficult charge at any age, young women face specific 
psychosocial and sexual issues that should be addressed by a multidisciplinary group of 
providers including breast nurses, breast oncologists and gynaecologists among others 
(LoE III). 
118
 
119
 
120
 Some supportive measures, including physiotherapy for arm mobility 
after axillary clearance, regular physical activity, weight loss if overweight or obese and a 
low calories diet are not age specific, but should be implemented also in the young 
patient population (LoE II). 
121 
 
 Smoking should be discouraged as it is associated with an increased risk of secondary 
tumours, including breast cancer (LoE III).
122
 Alcohol should be avoided as well, or limited 
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to one alcohol unit per day, as it increases the lifetime risk of breast cancer. Psychosocial 
support should be routinely offered also to spouse and children with directed 
interventions, if required (LoE III). 
123
 
124
 
125
Breast nurses (or experienced nurses) are of 
crucial important for the support of the patient and the family. 
Some of the specific issues for the young breast cancer population include:  
 
 
Premature menopause 
The risk of chemotherapy induced premature menopause is related to the agents used, 
the total dose delivered and patient’s age. 
126
 
127
 
 High cumulative doses of alkylating agents after the age of 35 years are associated with a 
high probability of premature menopause. Premature menopause remains a major 
concern for young women with breast cancer, and can influence therapeutic decisions 
and treatment adherence. 
128
 
129
 
130
 
131
There is some evidence that amenorrhoea is good 
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prognostic marker 
132
 but the therapeutic consequences of these preliminary data are not 
yet clear. 
Menopausal symptoms can be particularly bothersome in young patients with iatrogenic 
ovarian exhaustion. 
133
 Hot flashes can be reduced with nonhormonal treatments such as 
SSRI (Selective Serotonin Reuptake Inhibitors) (LoE I) 
134
 but attention should be paid to 
potential interactions of some of these agents with tamoxifen activity. Their combined 
action as antidepressants and hot flash reducers may be specifically helpful in young 
breast cancer patients where depression is significantly prevalent and often unaddressed. 
Fatigue, a common complaint in breast cancer patients, may be worsened by menopausal 
symptoms, insomnia and restlessness, and be of special concern in young patients who 
have to cope with multiple tasks linked to a young family, work and career. Other 
available non-hormonal treatments against hot flashes include gabapentine, clonidine 
and acupuncture. 
Infertility 
The risk of infertility is strictly related to that of premature menopause. Even women with 
regular menses after chemotherapy have a reduced ovarian reserveand experience 
impaired fertility and an earlier menopause. 
135
 This is mainly due to the direct toxicity of 
chemotherapy on the primordial ovarian oocyte pool, which physiologically diminishes 
with age and is significantly reduced after chemotherapy. Chemotherapy might also 
damage ovarian granulosa cells, thus accounting for menstrual irregularity during 
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treatment.
136
 The risk of genetic foetal anomalies, when pregnancy occurs during 
chemotherapy should prompt a thorough discussion about contraception before this 
treatment is initiated. 
Contraception 
Young women are potentially fertile also if they have menstrual irregularities or even if 
they are amenorrheic during or after treatment. 
137
Therefore, the issue of contraception 
needs to be addressed in all young BC patients (LoE III). Reliable and reversible 
nonhormonal methods including barrier methods (such as condoms, cervical diaphragm 
and copper IUDs) can be suggested (LoE III). For women asking for permanent 
contraception, laparoscopic tubal ligation or hysteroscopic tubal plugging can be used. In 
case of a steady partner, vasectomy is an option that needs to be discussed. The methods 
need to be chosen after thorough discussion with the woman/couple about the necessity 
of fertility preservation. Oestrogen- progestin containing contraceptives should not be 
used (LoE II), 
138
particularly not in women with endocrine-responsive BC. Although it is 
currently unknown if this also applies to non-endocrine-responsive disease, caution 
should be taken also in this subset of women. 
Cancer therapy-associated cognitive change (“chemobrain”)
139
 
Increasingly reported complaints include attention deficit, memory and concentration 
difficulties, which may affect cognition, psychological well being and the ability to 
perform professional and daily activities, a problem of special relevance in young patients 
committed to excellence at work and career. A randomized trial suggests that modafinil (a 
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novel wakefulness and alertness enhancing agent, with the potential to act as a cognitive 
enhancer without the side effects produced by other stimulants) may significantly 
improve speed of memory and quality of episodic memory, with improvement of 
continuity of attention in patients who continued the active treatment, with parallel 
significant improvement of the quality of sleep (another underevaluated complaint after 
chemotherapy). 
140
Unfortunately, this study does not specifically analyse the impact of 
the drug on the younger cohort of breast cancer patients. Cancer therapy-related 
cognitive decline, along with fatigue, anxiety and depression, are among the most 
common symptoms affecting the quality of life of breast cancer patients. They are 
becoming increasingly relevant, as post-treatment survivorship issues, with the 
improvement in survival of breast cancer patients seen in the last decades. In addition, 
cancer therapy associated cognitive changes may be affected by the menopausal status 
and its associated symptoms (insomnia, hot flashes, depression and anxiety) and 
comorbidities. Accurate understanding of the different potential contributors is crucial to 
optimise the treatment of this syndrome generically called “chemobrain”. 
Bone health 
Young women with chemotherapy-induced permanent amenorrhoea or those undergoing 
ovarian suppression may be considered at high risk for osteopenia/osteoporosis. Despite 
acting as a partial oestrogen agonist on the skeleton, tamoxifen can cause bone loss in 
premenopausal patients, probably because it has a weaker effect on bone than 
endogenous estrogens. As a consequence, in all young patients special emphasis on 
regular exercise and dietary education is needed (LoE III). Bone density scan monitoring 
may be considered and calcium (1000 mg/day) and vitamin D (800 UI/ day) supplements 
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can be recommended, especially in cases of lactose or gluten intolerance and/or when 
the diet is poor in calcium. Bisphosphonates should be prescribed according to the degree 
of bone loss. Current general guidelines in postmenopausal patients (including premature 
menopause either spontaneous or iatrogenic) recommend their use in case of 
osteoporosis but not osteopenia (LoE II). No general recommendation regarding the use 
of prophylactic bisphosphonates for bone health preservation can be made at the present 
time. 
 
 
Lymphoedema 
Lymphoedema is the second most feared complication after recurrence of breast cancer. 
It may affect 32– 40% of women undergoing axillary dissection and 1.8% of those 
undergoing sentinel lymph node biopsy. It may dramatically affect quality of life for 
functional and cosmetic reasons. Treatment may include drugs such as diosmine–
hesperidine that may increase lymph drainage and hence reduce lymphoedema, 
particularlyif started early. 
141
 It is also important to reduce modifiable risk factors such as 
high BMI, infection and injury. 
142
 Physiotherapy and strength training intervention can 
lead to significant improvement of lymphoedema, but particularly of mobility. 
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Sexual dysfunction 
Sexuality encompasses three major dimensions: sexual identity, sexual function and 
sexual relationship, which may be variably wounded in young women with breast 
cancer.
143
 
Sexual identity and body image are more vulnerable in younger women, 
144
 the breast 
being a prominent sign of femininity and beauty. If mastectomy is required, attention to 
immediate reconstruction and nipple sparing techniques (if oncologically feasible) to 
maintain the nipple sensitivity may positively improve the psychosexual outcome in terms 
of body image and sexual identity. 
Young women with breast cancer are at particular risk for sexual dysfunction, which is 
being increasingly reported during and after treatment. Prospective data indicate that the 
quality of sexual intimacy worsens over time, 
145
 with increasing percentage of women 
reporting sexual dysfunction. For vaginal dryness and dyspareunia, non-hormonal 
methods, including moisturizing and lubricating agents are preferred (LoE III) 
146
 Local 
estrogens with low/minimal (<1%) systemic absorption like promestriene could be 
helpful,
147
 yet few safety data in women with breast cancer are available. 
148
  
149
In women 
                                                           
143
 Graziottin A, Basson R. Sexual dysfunctions in women with premature menopause. Menopause 
2004;11(6):766–77. 
144
 Schover LR. Sexuality and body image in younger women with breast cancer. J Natl Cancer Inst Monogr 
1994;16:177–82. 
145
 Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML, Petersen L. Breast cancer survivors: psychosocial 
concerns and quality of life. Breast Cancer Res Treat 1996;38(2):183–99. 
146
 Graziottin A. Female sexual dysfunction: treatment. In: Bo K, Berghmans B, Morkved S, Van Kampen M, 
editors. Evidencebased physical therapy for the pelvic floor – bridging science and clinical practice. Oxford, 
UK: Elsevier; 2007. p. 277–87. 
147
 Santos I, Clissold C. Urogenital disorders associated with estrogen deficiency: the role of promestriene as 
topical estrogen therapy. Gynecol Endocrinol 2010;26(9):644–51. 
148
 Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously 
treated for breast cancer. Climacteric 2003;6:45–52. 
149
 Trinkaus M, Chin S, Wolfman W, Simmons C, Clemens M. Should urogenital atrophy in breast cancer 
survivors be treated with topical estrogens. Oncologist 2008;13:222–31 
 Management of a High Quality Comprehensive Breast Center 
155 
 
with oestrogen-receptor negative breast cancer twice a week vaginal estradiol or estriol, 
that has low systemic absorption and stronger efficacy on the vaginal mucosa, lubrication 
and vaginal ecosystem can be considered in cases with severe symptoms. Special 
attention should be devoted to the complaint of dyspareunia that can be triggered by 
vaginal dryness and worsened by the defensive contraction of the pelvic floor (levator ani 
muscle), more likely in childless women. While specific studies in breast cancer patients 
are lacking, in general patients with dyspareunia pelvic floor rehabilitation, levator ani 
stretching, electromyographical biofeedback aiming at relaxing the pelvic floor are 
supported by significant evidence (LoE II). If loss of desire and central arousal difficulties 
persist after correction of physical symptoms and depression, psychological support 
should be offered.
150
 Sexual relationship: breast cancer diagnosis and treatment may 
dramatically impair the quality of the couple relationship. Data indicate that the 
emotional intimacy, the sense of bonding, affection and commitment may be improved in 
the majority of couples (60–70%) while the physical, erotic intimacy may be variably 
affected. The longer the time is between surgery and having intercourse again, the higher 
the probability of sexual dysfunction. Patients and their partners should be reassured that 
there is no medical contraindication to sexual intimacy including touching the operated 
breast during breast cancer therapy and afterwards.
151
 These issues should be addressed 
promptly, as sexual prognosis improves if effective management/treatment is 
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implemented early (LoE III).
152
 Unfortunately, the quality of sexual life remains 
unaddressed in the majority of consultations, with a major burden for younger couples. 
Younger husbands seem to have the highest vulnerability as caregivers, as they have 
more difficulty in coping with the wife/partner illness and the responsibility of small 
children. 
153
Data indicate that addressing intimacy and partner communication in breast 
cancer patients may improve relationship adjustment
154
, with specific attention to young 
women with breast cancer. In post-diagnosis counseling, it is important not to overwhelm 
patients with too much information and too many issues. Time for a second or third 
discussion should be offered and referral for specific professional consultation should be 
facilitated within the context of the individual oncologic situation. 
Breast cancer and pregnancy 
…pregnancy after breast cancer? If you wish madam! ☺ 
Pregnancy after breast cancer 
All retrospective available data report not only no detrimental effect of a subsequent 
pregnancy on breast cancer outcome but also a potential favorable impact on prognosis. 
Therefore, pregnancy after breast cancer should not in principle be discouraged (LoE III). 
155
 
156
Nonetheless, a thorough staging should be performed before trying for conception, 
depending on the individual risk of relapse (LoE IV) and patients should be informed 
about the possibility of breast cancer recurrence even many years after diagnosis. 
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There is no definitive evidence to recommend a fixed time frame from diagnosis to 
pregnancy. Despite absence of supporting evidence, some experts recommend avoiding 
early pregnancy (within 2 years from diagnosis) in cases of higher risk of early relapse. In 
addition, potential disadvantages of early stopping of ongoing recommended anti-cancer 
treatments must be discussed and balanced with the risk of infertility due to ageing and 
iatrogenic effects of cancer treatment. In particular, women should be fully informed 
about the risk of stopping tamoxifen treatment prematurely (the earlier the interruption, 
the higher the risk of relapse). For the moment, it is recommended to complete 
endocrine therapy after pregnancy and an ongoing worldwide clinical trial is addressing 
this issue. A delay of pregnancy should be discussed on an individual basis in order to 
allow for continuation/completion of adjuvant therapy, and discussion should include 
taking into account the half life of administered treatment (to prevent detrimental effects 
on foetus), the detection of early relapse in high-risk disease and/or overcoming early 
treatment related side effects. In general, an interval of at least 4–6 months from the end 
of chemotherapy and the attempt to conceive is recommended (LoE expert opinion). 
Data on endocrine treatment are less conclusive: as a practical advice, an interval of at 
least 3 months from the end/interruption of therapy is recommended due to the half-life 
of tamoxifen. Limited data on the efficacy and safety of ovarian stimulation after 
treatment of breast cancer are available. Caution and individualised decision making are 
recommended. 
Data about pregnancy and foetal outcome after breast cancer treatment are reassuring. 
No increased foetal malformation rates have been reported after completion of 
chemotherapy or endocrine treatment, but some population-based data report an 
increased risk of delivery complications, caesarean section, very preterm birth (<32 
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weeks) and low birth weight (<1500 g), highlighting the need for careful pregnancy 
surveillance and management in this population. Breastfeeding after breast cancer is not 
contra-indicated and should be supported with adequate information and counselling. 
157
 
158
Milk production after breast conserving surgery and radiotherapy is reduced, but 
breastfeeding from the other breast is feasible and safe for the mother and the child, 
provided the patient is not taking any medications that may be harmful for the child (LoE 
III). 
If a woman prematurely stops endocrine treatment to achieve a pregnancy, resuming 
tamoxifen after breastfeeding completion can be considered (LoE expert opinion). 
Breast cancer during pregnancy 
In 2010 an international, multidisciplinary group met to update recommendations on 
treatment of breast cancer during pregnancy.
159
 
There are some key issues which need to be addressed in this particularly difficult 
situation. The experienced multidisciplinary team expanded to include obstetricians and 
perinatologists should decide on diagnostic and therapy interventions, on an individual 
basis. Any suspicious breast lump appearing during pregnancy should be clarified starting 
with ultrasonography. A core biopsy under local anaesthesia should be undertaken if 
doubt persists. To rule out multiple lesions or bilateral breast cancer, mammography can 
be recommended. Further staging using other imaging techniques should only be 
undertaken if the results would lead to an important change in the treatment approach. 
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Any type of therapy should follow the guidelines for non-pregnant women as closely as 
possible. Surgery can be safely performed, and the indications for mastectomy or breast 
conserving therapy are the same as for nonpregnant women. There are increasing data 
suggesting that sentinel node biopsy with radionuclide mapping can be safely performed 
during pregnancy, using a one day protocol to keep the radioactivity to a minimum. There 
is an important amount of data demonstrating that chemotherapy can be safely 
administrated to pregnant breast cancer patients using standard anthracycline- based 
regimens (e.g. FEC, FAC, EC, AC). These regimens should be followed by a taxane 
whenever indicated. The taxane can also be administered during pregnancy, although 
there are less available data. A more widely used approach is to administer the 
anthracycline- based part of the regimen during pregnancy and the taxane-based part, 
whenever indicated, after delivery. Since there are sufficient alternatives and given the 
potential foetal toxicity of M, CMF should not be used during pregnancy.  The regimens of 
chemotherapy recommended to pregnant breast cancer patients are the same as the 
ones recommended to non-pregnant counterparts. 
Trastuzumab and endocrine therapy must not be prescribed during pregnancy but must 
be postponed until after delivery. Radiotherapy should also be postponed until after 
delivery. Delivery should be done according to obstetrical needs with an interval of 2–3 
weeks between chemotherapy and delivery. It is believed that the risks associated with 
premature delivery are higher than the risks associated with chemotherapy 
administration during pregnancy. However, longer follow-up is needed in the several 
existent series of children whose mothers received chemotherapy during pregnancy, to 
better evaluate potential long term consequences. To increase the knowledge in this 
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specific patient population, the German Breast Group is coordinating an international 
prospective registry with translational research and pharmacokinetics studies associated. 
 
 
Nutrition and physical therapy 
The exact path that nutritional therapy takes may differ by cancer center and physician, 
but the core objective of achieving healthy weight loss or maintenance is the same. 
Dietitians specializing in oncology nutrition say it is critical that a nutritional program for 
breast cancer patients focus on maintaining a healthy weight during cancer treatments. 
Many breast cancer patients find themselves gaining weight during treatment. It’s not 
completely clear why this happens, but it appears that body composition often changes 
during treatment; muscle is lost while fat is gained. This can be a result of treatment itself 
as well as the fact that many people lower their physical activity while in treatment. And 
on top of lowered physical activity, calorie intake may increase as a result of food being 
prepared by family and friends as well as the misconception that all cancer patients lose 
weight, resulting in a focus on increasing calories. 
The exact components of nutrition therapy for patients with breast cancer will depend on 
the type of cancer they have, their treatment regimen, and their level of interest in 
nutrition and lifestyle therapy. However, all patients should undergo a nutrition screening 
by a healthcare provider or nutrition professional. This screening may then trigger a more 
comprehensive nutrition assessment and ongoing intervention or may result in simply 
referring them to the available nutrition resources in their area. 
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Many dietitians say that for a patient with early-stage breast cancer—which most have—
the dietary recommendations aren’t significantly different from ones they’d offer any 
patient focusing on healthy weight loss or maintenance. Because these patients aren’t 
dealing with malnutrition or anorexia issues, which are more typical in late-stage cases, 
the focus is on a balanced diet. For instance, breast cancer patients should eat 4 to 5 cups 
of colorful fruits and vegetables per day, consume plenty of fiber, include healthful fats 
such as cold-water fish and walnuts in their diet, get plenty of fluids, engage in daily 
physical activity, and limit alcohol consumption. 
The right nutrition program is not only helpful and healing to the body but also to the 
mind. Patients often embrace a nutrition plan for the feeling of control it gives them over 
their situation. Importantly, diet is one therapy that the patient can ‘control, while chemo 
and radiation are treatments that the patient attends but has little control over. This 
makes diet an important issue for the patient. They are seeking control at a time when 
they feel they have little. So it’s important to remember that an improvement in diet can 
not only increase their well-being but promote post-op healing, reduce the risk for 
comorbidities during and after cancer, and provide a sense of active participation in one’s 
own healing process. 
So many things about cancer are out of the patient’s control, but nutrition and healthy 
lifestyle are things they can control. Being empowered to make healthy choices through 
increased fruit and vegetables [intake], smart beverage choices, more physical activity, 
and proper portions can really improve the patient’s quality of life for the better, 
regardless of how it even affects weight. 
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For the patient to establish a relationship and know they’re going to meet with the same 
person each and every time is comforting. The dietitian becomes a credible resource to 
help weed through all the information out there. If you don’t have any opportunity to 
establish a relationship with your patient, you can’t expect any change. The patient needs 
someone on their side for the long term. It helps reinforce motivation and keeps the 
patient on track. 
While it seems obvious that a dietitian should be on the team of specialists helping 
patients through their breast cancer battle, it’s not always an option. 
The breast centre cancer nutrition team will work with the patient to decrease 
complications during breast cancer treatment. The dietitian will recommend diet 
modifications based on your breast cancer treatment regime, body weight, micronutrient 
deficiencies, and nutrition impact symptoms. In addition, the dietitian should work closely 
with other members of the care team in the breast centre, including gastroenterologist 
and naturopathic clinician. Together, they will recommend supplements and other 
therapies to support optimal digestion and nutrition, and help you further manage side 
effects of breast cancer treatment. 
Naturopathic medicine  
Naturopathic medicine is an approach to health care that uses natural, non-toxic 
therapies to treat the whole person and encourage the self-healing process. Naturopathic 
clinicians treat a variety of conditions, including digestive issues, respiratory conditions, 
chronic fatigue syndrome and cancer. 
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As part of integrative oncology services, naturopathic oncology providers focus on 
reducing the risk of harmful effects from cancer treatments. With a wide variety of 
natural therapies available, they select and propose the intervention that is appropriate 
for the patient’s health. Naturopathic oncology provider acts as a consultant to the breast 
centre’s oncologist to support normal metabolism and digestion during cancer treatment; 
manage any side effects, such as nausea or fatigue; and boost immune function. 
All of breast centre’s naturopathic oncology providers have extensive knowledge of 
radiation therapy, chemotherapy and other cancer treatments, in addition to their 
expertise in the effects of natural therapies. As a part of the care team, they are in regular 
communication with the oncologists and other clinicians to help guide treatment plan. 
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19. Conclusions  
I have tried to give a panoramic view of what a breast center should be. What I have 
learned from my work and what I want to transmit to you is that is not about the 
knowledge, at least not only about the knowledge. Of corse what makes us good doctors 
starts with learning and knowledge is the stone fundamental of our professional life.  
What all the statements I have made as my source of work have as their main goal is 
creating a well performing mechanism that needs not only the good will to cure cancer 
but needs a lot of research and calculation to make every piece of the all work together. 
It is not only about selecting a beautiful building, paint it pink, hire the best doctors and 
buying the most modern machines for the imaging. This is definitely not enough!!! What I 
have learned is that selecting doctors that   are specialized in radiology oncology or 
surgeons is not enough. To make their job perfect and the outcome as well perfect they 
have to be trained to cure in a special way the breast cancer, the study is not enough! As 
it is not enough having the most sophisticated imaging machines when there is no body 
capable to use and take care of them properly. 
As I have tried to explain in every chapter of my thesis is that to create there must be a 
well studied format for each part of the center and of course to make everything work 
probably there must be a leader at the head of it, a person who has experience in 
managing such a center and that knows all the protocols that make it work. 
Accordingto Eusoma (European Society of Breast Cancer Specialists) the fondamental 
requirements for a specialized breast center must:  
 Management of a High Quality Comprehensive Breast Center 
165 
 
1. Be a unic closely working entity 
2. Have at least  150 cases of newly diagnosed breast carcinoma per year, in order to ensure 
the efficiency of cost-benefit  ratio and to provide the right quantity of work for the team 
to be specialized in breast cancer care 
3. Ensure to have multidisciplinary team of experts in breast cancer care 
4. Have a multidisciplinary approach  
5.  Provide all the necessary services, from te screening and prevention to the diagnosis, 
treatment, follow up, genetic investigation and psychological support   
6. Have a database for all its cases 
7. Organize annualy a meeting with other experts in order to compare results and discus 
cases and research  
The main concept of all these raccomandations is to ensure a multidisciplinary 
approached from a specialized team to a not single entity disease as the breast cancer. 
The protocols are not made up ust to give the definition of the breast center and specify 
everybodys role in it, but also to make sure there will be good results of their work. 
European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis is 
the document where the quality indicators for such a center are discussed, based on 
experience and efficiency outcomes form different databases, physicians from different 
disciplines and specialized in breast cancer care created these guidelines. 
The experts have identified the quality indicators also taking into account the usability 
and feasibility. For each of them it has been reported: definition, minimum and target 
standard, motivation for selection and level of evidence (graded according to AHRO). In 
overall 17 main quality indicators have been identified, respectively, 7 on diagnosis, 4 on 
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surgery and loco-regional treatment, 2 on systemic treatment and 4 on staging, 
counselling, followup and rehabilitation. Two additional properties were of concern for 
selecting the most appropriate quality indicators: usability, which means the observations 
generated by the measured application are easily interpretable in order to prompt actions 
concerning healthcare delivery, and feasibility, that requires easy data collections during 
routine clinical activities with limited related costs.  
Working with regard to these quality indicators and also trying to reach the targets 
ensures a high quality treatment, decreases ansiety in patients lowering the waiting time 
and avoiding unnecessary procedures, lowers the costs and what is the most important 
lowers the mortality and increases life quality in these patients. 
I have talked about the mechanism and also about what makes it work but I have tried to 
make clear that the center of all this work are the patients. Women affected by breast 
cancer is what this high quality comprehensive breast center is about. 
Our patients deserve not only to be treated to deceive the beast that is threatening their 
life but also deserve to be understood and helped to make through the difficulty and 
changes that are going to be after that. 
Understanding what is important and being prepared to give the support they need is 
what makes our patients confident and helps them take the right decisions relying to the 
doctor’s advice and to the right information about the disease. 
Educating their family about our patient’s not only physical change but the need of 
psychological support is essential. Everything must resemble efficiency and reliability to 
the patients. 
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To reach in a conclusion without underestimating every kind of need our patient can 
need during the treatment patient we have to collaborate with the right colleagues in the 
right time with the right tools. 
Being first a good doctor and also knowing to manage every kind of situation trying to 
reach good results and optimize the own work relying to selected colleagues makes the 
gold standard of a high quality comprehensive breast center. The guidelines and the 
protocols are the ones that determine a center. 
It would be perfect to apply this format just relying to what is written black over white 
and guides our work, but to have the perfect outcome we have to consider not only them 
but also the women’s role in the society, the religious restriction and the lack of 
information that can make our work a little different of what we are told from the 
guidelines. 
“She was afraid of her immeasurable fear. She was afraid of that disease, the plague of 
the modern era. She was terrorized from this threatening coming out of no one knows 
where without any known reason that can go everywhere without any respect of race, 
rank, richness or culture. This was the ruthless enemy, resembling to a medusa head, 
which scatters in her the fear of fear. Of what is worth healing from cancer if you die from 
the fear!!!!!”- Sveva Casati Modignani – Disperatamente Giulia   
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